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Alzheimer’s disease (AD) is a multifactorial neurodegenerative disease. It begins years
prior to the onset of clinical symptoms, such as memory loss and cognitive decline.
Pathological hallmarks of AD include the accumulation of β-amyloid in plaques and
hyperphosphorylated tau in neuroﬁbrillary tangles. Copper, iron, and zinc are abnormally
accumulated and distributed in the aging brain. These metal ions can adversely contribute
to the progression of AD. Dysregulation of cholesterol metabolism has also been implicated
in the development of AD pathology.To date, large bodies of research have been carried out
independently to elucidate the role of metals or cholesterol on AD pathology. Interestingly,
metals and cholesterol affect parallel molecular and biochemical pathways involved in AD
pathology.The possible links between metal dyshomeostasis and altered brain cholesterol
metabolism in AD are reviewed.
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INTRODUCTION
Alzheimer’s disease (AD) is a multifactorial neurodegenerative
disease characterized by pathological hallmarks of extracellular
β-amyloid (Aβ) plaques (Glenner and Wong, 1984a,b; Masters
et al., 1985) and intracellular neuroﬁbrillary tangles (Delacourte
and Defossez, 1986; Kosik et al., 1986; Lee et al., 1991) in the brain.
The rate of ADprogression is variable, but on average, patientsmay
live up to 10 years after diagnosis (Whitehouse, 1997). Approxi-
mately 8–10% of the population over the age of 65 have AD, and
its prevalence doubles every 5 years thereafter (Cummings, 2004;
BertramandTanzi,2005). These data, coupledwith ever increasing
life expectancy,marksAD as one of themost signiﬁcant health and
socio-economic problems, particularly in industrialized nations.
As with most diseases, genetic and environmental factors can
contribute to its development. AD can be broadly characterized
as either familial or sporadic. Early-onset familial AD (FAD) are
caused by mutations within three genes, which encode the amy-
loid precursor protein (APP) and presenilins 1 and 2 (PSEN1
and PSEN2; Holmes, 2002; Tanzi and Bertram, 2005; Bertram
et al., 2007). Thesemutations are autosomal dominant, and symp-
toms of AD manifest prior to 65 years of age. FAD accounts
for less than 5% of AD cases (Janssen et al., 2003; Raux et al.,
2005). The disease etiology for late-onset sporadic AD is com-
plex and multifactorial, which may involve age-related alterations
in metabolism, repair mechanisms, immune response, and envi-
ronmental factors such as life style, prior brain trauma, and
oxidative stress (Muller-Spahn and Hock, 1999; Chen et al., 2009).
Genome-wide association studies (GWAS) have identiﬁed candi-
date genes that signiﬁcantly increase the risk of late-onset AD.
By far, the strongest risk factor found is the ε4 allele of the
apolipoprotein E (APOE) gene (Farrer et al., 1997). Possessing
just a single ε4 allele increases the risk of developing AD by
two- to ﬁvefold, while having two alleles increases the risk to
more than ﬁvefold (Poirier et al., 1993; Strittmatter et al., 1993;
Holmes, 2002; Poirier, 2003; Bertram et al., 2007; Coon et al.,
2007).
Neuritic plaques are multi-cellular lesions containing Aβ pep-
tides (especially the neurotoxic Aβ42 species), reactive astro-
cytes, activated microglia, and dystrophic neurites (Maulik
et al., 2013). Aβ peptide is produced by the proteolytic cleav-
age of APP by β- and γ-secretases (see APP Processing and Aβ
Generation). Interestingly, these plaques also have an enrich-
ment of cholesterol (Panchal et al., 2010) and metals such
as copper, iron, and zinc (Goodman, 1953; Connor et al.,
1992; Bush et al., 1994c; Lovell et al., 1998; Suh et al., 2000;
Collingwood et al., 2005; Stoltenberg et al., 2005; Miller et al.,
2006; Baltes et al., 2011), which indicate a failure of choles-
terol and metal regulatory systems in the brain. While the
underlying etiology of AD is yet to be clearly established,
mounting evidence derived from epidemiological, clinical and
biochemical studies have independently implicated roles for met-
als and cholesterol in the pathogenesis of AD. This review
presents an overview of the roles of metals and cholesterol in
APP/Aβ metabolism and their relationship in the development
of AD.
APP PROCESSING AND Aβ GENERATION
Amyloid precursor protein is a type I trans-membrane protein that
can be post-translationally modiﬁed by N- and O-glycosylation,
tyrosine sulfation, and phosphorylation (Weidemann et al., 1989;
Walter et al., 2000). Full-length APP is sequentially processed via
two pathways: the non-amyloidogenic and amyloidogenic. The
cleavage by α- or β-secretases at the N-terminus of the Aβ domain
generates soluble APP derivatives: sAPPα and sAPPβ, respectively,
leaving behind membrane tethered C-terminal fragments (CTFα
and CTFβ, respectively). Subsequent cleavage of these CTFs by the
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γ-secretase generates either p3 (from CTFα) or Aβ (from CTFβ),
and liberation of the APP intracellular domain (AICD; reviewed
in Zheng and Koo, 2011; Figure 1B).
The trans-membrane aspartyl protease β-site APP cleaving
enzyme 1 (BACE1) is the major β-secretase in neurons (Sinha
et al., 1999). This is the rate-limiting enzyme involved in the gen-
eration of Aβ (Vassar et al., 1999; Yan et al., 1999). In contrast,
α-secretase cleavage of APP can be stimulated by a disintegrin
and metalloproteinase (ADAM) family of proteases (reviewed
in Lichtenthaler, 2011) and a number of other molecules (e.g.,
phorbol ester) or via protein kinase C activation, in which case
the cleavage is regulated by tumor necrosis factor α-converting
enzyme (TACE; Buxbaum et al., 1998; Blacker et al., 2002). Stud-
ies have indicated that in neurons, α-secretase activity is likely
to be primarily mediated by ADAM10 (Kuhn et al., 2010). The
mature γ-secretase is a polytopic complex consisting of four
individual components: presenilin (PS); nicastrin (Nct); ante-
rior pharynx defective 1 (Aph1); and presenilin enhancer 2
(Pen-2; reviewed in Edbauer et al., 2003; Iwatsubo, 2004). Pre-
senilin, an aspartyl protease, is the main catalytic unit of the
complex. Aβ of varying length is the result of hierarchical and
site-speciﬁc cleavage of APP by β- and γ-secretase (Figure 1B).
FIGURE 1 |The involvement of metals and cholesterol in
post-translational modification ofAPP. (A) Schematic of reported metal and
cholesterol binding domains in APP770 and Aβ in relation to other recognized
motifs. APP770 is the longest isoform of APP with the APP751 isoform lacking
the OX-2 domain and the neuron prevalent isoform APP695 lacking both OX-2
and Kunitz-type protease inhibitor (KPI). Within the extracellular presented
ectodomain of APP, the E1 region at the N-terminal contains a copper binding
domain (CuBD) and zinc binding domain (ZnBD) that is C-terminally orientated
compared to the growth factor domain (GFD) which incorporates a heparin
binding domain (HEPBD). The E1 domain is followed by the acidic region (AR),
KPI and OX-2 before the E2 domain of APP, containing a HEPBD and
CuBD/ZnBD that is yet to be exactly mapped (Dahms et al., 2012). The E2
domain is followed by the Aβ peptide that is partially embedded into the
transmembrane region. Aβ also has a recognized CuBD/ZnBD as well as a
Cholesterol binding region (CholBD) that incorporates the GXXXG motifs.
(B) Proteolytic processing of APP predominantly follows two pathways that
are initiated by separate secretases. The non-amyloidogenic pathway (blue
arrows) initiates with the cleavage of full-length APP by α-secretase within
the Aβ sequence. Following further cleavage by the γ-secretase complex, this
pathway results in the generation of soluble N-terminal APP fragment (sAPPα)
and C-terminal fragments (p3 and AICD). The alternative amyloidogenic
pathway (red arrows) involves sequential cleavage of APP by β-secretase
followed by the γ-secretase complex, which results in the liberation of a
soluble N-terminal sAPPβ fragment, Aβ peptide, and AICD. Copper and zinc
affect the processing of APP and Aβ generation on neuronal membranes
through their direct inﬂuence on the enzymatic activity of β-, α-, and
γ-secretases. The inﬂuence of cholesterol is through its requirement in lipid
raft domains, the location for amyloidogenic processing of APP.
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Other than APP, all three APP-cleaving secretases can digest
other biological substrates required for multiple biological func-
tions such as regulation of development, differentiation, and
proliferation.
METAL AND CHOLESTEROL MODULATION OF APP AND Aβ
METABOLISM
The dynamics of biologicalmetal ions (e.g., copper, zinc, and iron)
is critical for many physiological functions. Metal ions are key
components in many enzymatic functions, which include catal-
ysis, structural stability, transportation of oxygen, and cellular
signaling. The passive ﬂux of metals between the circulation and
the brain is tightly regulated by the blood–brain barrier (BBB;
Duce and Bush, 2010). The impact of metals on the brain causing
neurodegeneration may be caused by increased toxic exposure, as
well as a breakdown in the mechanisms that compartmentalize
and regulate metal homeostasis.
The brain is the most cholesterol-rich organ in the body. Func-
tionally, cholesterol plays a critical role in neuronal development
and maintenance of synaptic plasticity. As a component of the
plasma membrane, it regulates ion homeostasis, endocytosis, and
intracellular signaling pathways. It also serves as a precursor for
the production of steroid hormones, vitamin D, and oxysterols.
Like metals, experimental work has shown compartmentalization
between levels of cholesterol in the serum and brain that is regu-
lated by BBB (Hung et al., 2013). Substantial evidence correlates
cholesterol homeostasis dysregulation with AD. In cell culture
systems, production of Aβ is linked to cholesterol levels. How-
ever, the exact inﬂuence of cholesterol in Aβ generation is still
unclear.
METALS AND APP
The APP sequence contains putative binding sites for copper
(Hesse et al., 1994; Atwood et al., 2000; Simons et al., 2002; Barn-
ham et al., 2003; Valensin et al., 2004) and zinc (Bush et al., 1993,
1994a,b,c). Copper binds to APP between residues 142 and 166
(White et al., 1999a; Barnham et al., 2003), a site where it can
also catalytically reduce copper (Multhaup et al., 1996). Recently,
two copper binding residues at histidine 149 and 151 have been
identiﬁed as crucial for APP metabolism, protein folding and sta-
bility (Spoerri et al., 2012). The Aβ segment of APP is another
region that directly interacts with copper and is explained in
more detail in Section “Metal Modulation of Aβ Generation,
Aggregation, and Cell Toxicity.” The N-terminal copper bind-
ing domain of APP has been found to play crucial roles in
homodimerization (Hesse et al., 1994; Kaden et al., 2008), and
an elevation in copper levels increases APP homodimerization
(Noda et al., 2013). Zinc binds to a conserved region of amino
acids between position 170 and 188 of APP (Bush et al., 1993,
1994a). The coordination binding involves two key cysteines at
positions 186 and 187, as well as other potential ligands (e.g.,
C174, M170, D177, and E184). Similar to copper, the binding of
zinc may also play an important functional role in homodimer-
ization of APP (Scheuermann et al., 2001; Ciuculescu et al., 2005;
Figure 1A).
A number of in vivo and in vitro studies highlight the recip-
rocal regulation between APP and metal ions. The regulation
of APP gene expression is linked to altered cellular copper
levels. Studies in the in vitro cell culture show that copper
depletion by overexpressing copper transporter ATP7A result in
down-regulation of APP gene expression and APP protein level;
conversely, APP gene expression level is up-regulated under con-
ditions of copper overload due to ATP7A-deﬁciency (Armendariz
et al., 2004; Bellingham et al., 2004b). On the other hand, cop-
per concentration is increased in brain and liver tissue as well as
primary neuronal and skin ﬁbroblast cells from APP and amy-
loid precursor-like protein 2 (APLP2) knockdown mice (White
et al., 1999b; Bellingham et al., 2004a; Hung et al., 2009; Acevedo
et al., 2011). The difference in copper level is even more pro-
nounced in aged mice (Needham et al., 2014). In contrast, APP
over-expressing transgenic mice have decreased copper in the
brain (Maynard et al., 2002; Bayer et al., 2003; Phinney et al.,
2003). Copper treatment stimulates the movement of APP from
the trans-Golgi network to the plasma membrane and attenu-
ates internalization of APP to BACE1-rich endosomes. However,
copper treatment does not result in any detectable change in
APP processing (Hung et al., 2009; Acevedo et al., 2011). In
humans, low copper diet is associatedwith a signiﬁcant decrease in
APP expression in platelets from healthy postmenopausal women
(Davis et al., 2000).
Iron regulates APP translation, which involves an iron response
element (IRE) RNA stem loop in its 5′-untranslated region
(UTR). The APP IRE is homologous with the canonical IRE
RNA stem-loop that binds iron regulatory proteins (IRP1 and
IRP2) to control intracellular iron homoeostasis by modulat-
ing ferritin mRNA translation and transferrin receptor mRNA
stability (Rogers et al., 2002). IRP1, but not IRP2, selectively
binds to the APP IRE in human neural cells (Cho et al.,
2010). Intracellular metal chelation selectively down-regulates
APP 5′-UTR translation, which is reversed by cytoplasmic
labile iron (Venti et al., 2004). The regulation of APP by iron
through the 5′-UTR indicates that iron has a role in APP
metabolism.
In the brain, ferroportin (Fpn) is required for excess iron to exit
the cell (Donovan et al., 2005; Ganz, 2005). Fpn channels trans-
port iron through the plasmamembrane where it is required to be
converted to its ferric form before being released and loaded onto
transferrin, the extracellular iron-transporting protein that trans-
fers iron between cells (Swaiman and Machen, 1984). APP may
play a role in the iron export mechanism of cells through the sta-
bilization of Fpn (Duce et al., 2010). APP knockout mice exposed
to dietary iron results in ferrous iron accumulation and oxidative
stress in cortical neurons. Ablation of APP in HEK293T cells and
primary neurons negates iron export, which can be restored by the
addition of exogenous APP (Duce et al., 2010). This iron-export
capability of APP requires tau to trafﬁc endogenous APP to the
cell surface (Lei et al., 2012).
CHOLESTEROL AND APP
Cholesterol is not symmetrically distributed laterally and between
the two leaﬂets of the lipid membrane bilayer. The signiﬁ-
cance of this asymmetry is not yet known, although choles-
terol has been implicated in cell membrane ﬂuidity, integrity,
and function (Wood et al., 1999; Hayashi et al., 2002). Patches
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of the membrane highly enriched with cholesterol and sphin-
golipid are termed lipid rafts (also known as detergent-resistant
microdomains). Cholesterol provides structural stability in rafts
by serving as a molecular spacer, ﬁlling in voids between raft
proteins and other raft lipids such as sphingolipids and gan-
gliosides (Xu and London, 2000; Ramstedt and Slotte, 2006).
Therefore, modulation of cholesterol can result in dissociation,
dysregulation, and/or inactivation of raft proteins. Indeed, APP
processing and activity is inﬂuenced by its membrane domain
localization.
Binding of cholesterol to APP occurs in the trans-membrane
carboxyl-terminal region between amino acids 672 and 770
(or CTFβ) through interactions with membrane-buried GXXXG
motifs (G, glycine; X, any amino acid; Barrett et al., 2012;
Figure 1A). The GXXXGmotif is involved with APP homodimer-
ization (Kim et al., 2005; Munter et al., 2007; Kienlen-Campard
et al., 2008; Miyashita et al., 2009; Sato et al., 2009). Competitive
studies of C99 with cholesterol suggest that complexing of choles-
terol:C99 at a 1:1 ratio is preferred over C99 homodimers under
most physiological conditions (Song et al., 2013). The binding of
cholesterol directly to APP and CTFβ may promote amyloido-
genic processing by increasing the localization of APP/CTFβ to
cholesterol-rich membrane domains and organelles, where γ- and
β-secretases preferentially reside (Beel et al., 2010).
In cultured rat neuronal cells, up-regulation of APP gene
expression reduces cholesterol biosynthesiswhile down-regulation
of APP gene expression has the opposite effect (Pierrot et al.,
2013). Membrane cholesterol content, however, is not affected.
Sterol receptor element binding protein (SREBP) and rate lim-
iting enzyme HMG-CoA reductase (HMGCR) control biosyn-
thesis of cholesterol. The site-2 zinc metalloprotease (S2P)
cleaves SREBP at Site-2 within the membrane-spanning domain
(Brown and Goldstein, 1999). Interaction of APP with SREBP1
prevents S2P-mediated processing of mSREBP1 nuclear trans-
lation of its target genes including HMGCR (Pierrot et al.,
2013). Interestingly, the APP/Aβ GXXXG motif is critical
in the regulation of HMGCR. In contrast to neuronal cells,
APP interaction with SREBP1 and resulting cholesterol biosyn-
thesis is not detectable in astrocytes (Pierrot et al., 2013).
APP expression associated reduction of cholesterol and oxys-
terol production is mediated via down-regulation of both
HMGCR and 24-hydroxylase [required to convert cholesterol
to 24S-hydroxycholesterol (24OHC)] activities, respectively.
Since membrane cholesterol remains the same, it is sug-
gested that APP controls cholesterol turnover (Pierrot et al.,
2013).
METAL MODULATION OF APP PROCESSING ENZYMES
Metals can indirectly affect Aβ generation by altering secretase-
dependent processing of APP. To date, all three secretases involved
in APP cleavage are known to have interactions with different
metal species. The α-secretase TACE contains a zinc ion in its
catalytic domain (Cross et al., 2002). TACE enzymatic activity is
controlled by a“cysteine-switch”motif mediated by an intramolec-
ular bond between cysteine and a zinc atom in its catalytic
site. Subsequently, it has been shown that other regions of the
TACE prodomain are able to circumvent the “cysteine-switch” and
inhibit enzymatic activity (Buckley et al., 2005). Correspondingly,
the metalloprotease ADAM10 can be inhibited by its dominant-
negative form that has a point mutation in its zinc-binding site
(Lammich et al., 1999).
The major β-secretase BACE1, binds copper in its C-terminal
domain, the same region that interacts with domain I of cop-
per chaperone for superoxide dismutase-1 (CCS; Angeletti et al.,
2005). The expression of BACE1 reduces superoxidase 1 (SOD1)
activity. In contrast, in cells overexpressing both BACE1 and
CCS, SOD1 activity is restored by CCS (Angeletti et al., 2005).
An interaction between BACE1 and CCS has been demonstrated
by co-immunoprecipitation from brain homogenates and their
co-transport through the axon (Angeletti et al., 2005).
Presenilin, the active subunit of the γ-secretase, is also sensitive
tometal levels. Neonatal cortical cultures exposed to zinc increases
C-terminal fragmentation of PS1 by enhancing synthesis of the
protein (Park et al., 2001). However, zinc induces oligomerization
of an APP γ-secretase substrate and inhibits its processing, which
supports a role for zinc dysregulation inAβ processing (Hoke et al.,
2005; Greenough et al., 2011).
Taken together, these results suggest a direct inﬂuence of met-
als on secretase enzymatic activity to process APP and therefore
may have detrimental implications in AD pathology when metal
homeostasis is altered.
CHOLESTEROL MODULATION OF APP PROCESSING
Previous studies show that full-length APP, Aβ, APP-CTFs, and
PS1 are associated with lipid rafts (Lee et al., 1998; Simons et al.,
2001; Hur et al., 2008). Studies with cultured cells demonstrate
cholesterol depletion by β-cyclodextrin extraction or inhibition of
cholesterol biosynthesis by statins (Simons et al., 1998; Wahrle
et al., 2002), result in decreased Aβ production. Conversely,
increasing cellular cholesterol levels enhance Aβ production and
reduce α-secretase cleavage of APP (Bodovitz and Klein, 1996;
Frears et al., 1999).
Since APP, β- and γ-secretases are associated with lipid raft
domains, it is not surprising that altered cellular cholesterol
content affects Aβ generation, aggregation, and clearance. The
presence of lipid raft domains has been found in plasma mem-
branes and endosomes. More recently, a study uncovered lipid
raft-like domains in mitochondria-associated endoplasmic retic-
ulum (ER) membranes (MAMs), a sub-compartment of the ER
connected to mitochondria (Area-Gomez et al., 2012). Lipid rafts
are sensitive to altered cholesterol metabolism, and cholesterol
depletion results in lipid raft destabilization (Eckert et al., 2010).
As previously mentioned, cholesterol enriched in lipid rafts can
inﬂuence dynamics of proteins within these rafts. Altered choles-
terol levels affect lipid raft localization of APP and its derivatives
together with secretases required for APP processing. Biochem-
ical isolation of lipid rafts indicates that BACE1 and γ-secretase
protein are localized within these lipid domains (Wahrle et al.,
2002; Vetrivel et al., 2004; Kalvodova et al., 2005; Osenkowski
et al., 2008), while the α-secretase ADAM10 is predominantly
localized outside the lipid rafts (Kojro et al., 2001). Consistent
with other lipid raft domains, MAMs have a high concentration
of APP, PS1, and PS2 (catalytic subunits of γ-secretase) and γ-
secretase activity. APP is believed to exist in either pool within
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plasma membranes (Ehehalt et al., 2003). Experimental evidence
suggests that amyloidogenic processing of APP occurs in lipid
rafts while the non-amyloidogenic processing occurs mainly in
the non-raft regions. If this is the case, then cholesterol lev-
els contribute to regulation of APP processing through these
two pathways. The non-amyloidogenic pathway predominates,
because only small amounts of APP appear to be present in
lipid rafts under physiological conditions (Bouillot et al., 1996;
Parkin et al., 1999). Increasing membrane cholesterol levels may
increase overall percentage of lipid rafts, which favors APP and
BACE1 interaction and increases Aβ generation. Several studies
support this idea. Firstly, imaging of ﬂuorescently tagged APP and
BACE1 demonstrates that cholesterol loading does not increase
Aβ production through BACE1 catalytic activity but rather by
altering the accessibility of BACE1 to its substrate APP in lipid
rafts (Marquer et al., 2011). Secondly, APP and BACE1 copatch
at the plasma membrane upon antibody cross-linking, which
increases Aβ production in a cholesterol-dependentmanner (Ehe-
halt et al., 2003). Lastly, inhibition of γ-secretase activity leads
to an accumulation of APP-CTFs in lipid rafts (Vetrivel et al.,
2004).
Niemann–Pick type C disease (NP-C) is a lysosomal lipid
storage disorder, characterized by accumulation of cholesterol
and sphingolipids within the endosomal–lysosomal system. The
majority of NP-C cases are caused by functional loss of NPC1
protein activity, due to genetic mutation. Neuronal degenera-
tion underlies neurological symptoms in NP-C patients, which
include cerebellar ataxia, dysphagia, dysarthria, and dementia.
Altered cholesterol distribution within subcellular compartments
has been implicated in the aberrant trafﬁcking and processing of
APP similar to that observed in AD (Runz et al., 2002; Vanier
and Millat, 2003; Jin et al., 2004; Walkley and Suzuki, 2004;
Vance, 2006; Kodam et al., 2010; Kosicek et al., 2010; Malnar
et al., 2010, 2012). In cell models of NP-C, cholesterol over-
load due to NPC1 deﬁciency leads to increased APP lipid raft
localization and internalization from the plasma membrane to
BACE1-rich endosomes, where amyloidogenic processing occurs
(Kosicek et al., 2010; Malnar et al., 2010). This can be corrected
by cholesterol depletion in cultured cells using lipid-deﬁcient
serum, lovastatin treatment, or methyl-β-cyclodextrin treatment
(Malnar et al., 2012). The cholesterol-dependent change in APP
trafﬁcking and lipid raft localization parallels previous studies
of APP’s response to changes in cellular copper levels (Hung
et al., 2009; Acevedo et al., 2011). Furthermore, cholesterol-
dependent APP trafﬁcking and metabolism may explain some
of the metal changes observed in NP-C tissue samples (Hung
et al., 2014). Taken together, these evidences suggest a syner-
gistic interaction between copper and cholesterol pathways in
the regulation of APP metabolism that may contribute to AD
pathogenesis.
Altered intracellular cholesterol metabolism can also affect
APP processing. Cultured cells exposed to a cholesterol transport
inhibitor, U18666A, accumulate cholesterol in late endosomes and
lysosomes, and results in a dose-dependent decrease inAβ produc-
tion (Runz et al., 2002; Davis, 2008). However, the inhibitor also
increases accumulation of γ-secretase, CTFβ, and Aβ-related pep-
tides in vesicular organelles (Runz et al., 2002; Jin et al., 2004).
From these studies, it can be inferred that cholesterol is able to
inﬂuence APP processing through re-internalization of surface
APP, as well as redistribution of APP and its processing enzymes
within subcellular compartments.
METAL MODULATION OF Aβ GENERATION, AGGREGATION, AND CELL
TOXICITY
Aβ binds to zinc, copper, and iron to form various precipitous
complexes, which are dependent on pH, buffer conditions, and
initial peptide aggregation rate (Bush et al., 1994b; Huang et al.,
1997; Garai et al., 2006; Tougu et al., 2008). Human Aβ bind-
ing of zinc, and both oxidized and reduced copper (Bush et al.,
1994c; Atwood et al., 2000; Syme et al., 2004; Syme andViles, 2006;
Danielsson et al., 2007; Himes et al., 2008; Karr and Szalai, 2008;
Shearer and Szalai, 2008; Hureau and Faller, 2009) is mediated by
nitrogen ligands from histidine at positions 6, 13, and 14 together
with an oxygen ligand (Curtain et al., 2001). Interestingly, rat and
mouse have different amino acids at the metal ion coordination
site, which could explain why these animals resist developing amy-
loid pathology compared to othermammals (Gaggelli et al., 2008).
More details regarding the biophysical and biochemical binding of
Aβ and the abovementionedmetals have been reviewed (Faller and
Hureau, 2009; Rozga et al., 2009).
Neurotoxic effects of Aβ depend on peptide aggregation, metal
ion interaction, and generation of reactive oxygen species (ROS)
with the subsequent formation of soluble covalently cross-linked
oligomers. Both Cu:Aβ and Fe:Aβ complexes have been shown to
exhibit cytotoxic effects (Schubert and Chevion, 1995; Liu et al.,
2011; You et al., 2012), which can be rescued by chelation or com-
petitive binding (Huang et al., 2004;Wu et al., 2008; Perrone et al.,
2010). Interestingly, it has been shown that modifying copper
binding histidine 6 or 13 to alanine induces signiﬁcant cell toxicity
in primary cortical cell cultures at levels similar to the wild-type
peptide (Smith et al., 2010). However, modifying histidine 14 (a
known ligand for copper and the cell plasma membrane), did
not induce any measurable toxicity that correlates with the ability
of the modiﬁed peptide to bind to cell membranes (Smith et al.,
2010).
Under normal physiological conditions, non-toxic monomeric
forms of Aβ are the predominant species (Haass et al., 1992; Vigo-
Pelfrey et al., 1993; Shoji, 2002). However, pathological stimuli are
thought to trigger complex conformational changes and assembly
of Aβ peptides to form a heterogeneous mixture of oligomers and
ﬁbrils. This aggregation of Aβ is a critical event for neurotoxicity to
occur. Soluble Aβ oligomers, and not ﬁbrils, are currently consid-
ered the proximate neurotoxin in AD pathology (Dahlgren et al.,
2002; Kayed et al., 2003; Cleary et al., 2005; Haass and Selkoe, 2007;
Lesne et al., 2008; Roychaudhuri et al., 2009; Shankar and Walsh,
2009). However, as both Aβ oligomers and ﬁbrils can interact
synergistically with tau and cause mitochondrial function impair-
ment in the P301L tau transgenic mouse model (Eckert et al.,
2008), the distinction in all forms of neurotoxicity between Aβ
species is not clear. Both copper and iron have been shown to
modify Aβ and accelerate its aggregation in vitro (Mantyh et al.,
1993; Atwood et al., 2000; Ali et al., 2005). Oxidation of the Aβ
side-chain by copper leads to covalent oligomerization (Ciccoto-
sto et al., 2004; Ali et al., 2005). Tyrosine at position 10 of Aβ is
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particularly susceptible to free radical attack. When complexed to
Cu2+ or Fe3+ and in the presence of H2O2, Aβ forms dityrosine
cross-linked oligomers, which are suggested to seed accelerated
Aβ aggregation (Atwood et al., 1998, 2004; Barnham et al., 2004).
Unlike zinc, copper mediates Aβ oligomer formation rather than
amyloid ﬁbrils, and thus Aβ:Cu oligomers are not recognized by
the β-sheet marker, thioﬂavin T (Jiao and Yang, 2007; Tougu et al.,
2009).
Investigations on metal-mediated modulation of Aβ have been
carried out in APP transgenic models supplemented with either
dietary copper or zinc. Administration of copper to APP23 mice,
overexpressing human APP with the AD-related Swedish muta-
tion, elevated copper levels in the brain compared to wild-type
littermate controls, resulting in a lowering of soluble and insoluble
Aβ (Bayer et al., 2003). Dietary zinc supplementation also reduced
Aβ plaques in brains of Tg2576 (another transgenic mouse model
carrying the Swedish-APP mutation) and TgCRND8 (a triple
transgenic mouse model carrying APP with Swedish and Indi-
ana mutations). However, AD-like spatial memory impairments
are increased in the zinc-fed transgenicmice (Linkous et al., 2009).
Conversely, decreased dietary zinc in a APP/PS1 transgenic mouse
model of AD elevated plaque volume (Stoltenberg et al., 2007).
Elevation of brain copper by crossing TgCRND8with a transgenic
mouse model deﬁcient in the copper transporter, ATP7B, reduces
plaque load as well as soluble and insoluble Aβ levels (Phinney
et al., 2003). These evidences suggest that an intracellular shift in
copper reduces Aβ aggregation.
Intracellular zinc export takes place through the zinc trans-
porters (ZnT) protein family. Currently eight ZnTs are known,
of which, ZnT-1 is the only member that exports zinc across the
plasma membrane within the brain (Lovell et al., 2005). ZnT-3
transports zinc to glutamatergic vesicles in hippocampal granule,
pyramidal, and interneuron cells (Cole et al., 1999; Linkous et al.,
2008), ZnT-4 sequesters cytosolic zinc into acidic vesicles (Kelleher
and Lonnerdal, 2002) and ZnT-6 sequesters zinc in the trans-
Golgi network and vesicular compartments (Huang et al., 2002).
The highest concentration of labile zinc is present in synaptic
vesicles that are released during synaptic transmission of neocor-
tical glutamatergic ﬁbers. As mentioned, the activity of ZnT-3 is
required for the passage and pooling of zinc within these pre-
synaptic vesicles, making it available for an interaction with the
Aβ that is predominantly located within the synapse. Crossing of
ZnT-3 knockout mice with Tg2576 mice, reduces both cerebral
plaque load (Lee et al., 2002) and amyloid angiopathy (Friedlich
et al., 2004). This supports the theory that high concentrations
of zinc in the synaptic cleft play a role in amyloid formation
in AD.
Oxidative stress-induced damage of brain tissues is a major
hallmark of AD. The redox chemistry involved in the produc-
tion of toxic ROS from metal enriched Aβ complexes and general
metal dyshomeostasis is implicated in this process. Binding of
oxidized copper or iron to Aβ results in reduction of the metal
valency state and subsequent production of H2O2 (Huang et al.,
1999; Opazo et al., 2002; Tabner et al., 2002; Nelson and Alkon,
2005). This can be further exacerbated by the reaction of hydro-
gen peroxide with reduced metal to produce hydroxyl radicals
through Fenton and Haber–Weiss reactions (Fenton, 1894; Haber
and Weiss, 1934). Hydroxyl radicals are highly chemically reac-
tive and contribute to generation of lipid peroxidation products,
protein carbonyl modiﬁcations, and nucleic acid adducts such as
8-hydroxy guanosine, all of which feature strongly in AD neu-
ropathology (Smith et al., 1996, 1997). Of note, evidence suggests
that the biological reductants involved inAβ redox cycling aremost
likely cholesterol and long chain fatty acids (Opazo et al., 2002;
Barnham et al., 2004; Haeffner et al., 2005; Nelson and Alkon,
2005; Puglielli et al., 2005; Smith et al., 2006). This is consistent
with experimental evidence demonstrating that toxicity associ-
ated with Aβ occurs on the plasma membrane (Ciccotosto et al.,
2004). Additionally, the products of lipid oxidation such as oxys-
terols, 7β-hydroxycholesterol and 4-hydroxy-2-nonenal, which in
turn increases Aβ cross-linking (Murray et al., 2005), are elevated
in AD tissues andmouse models of the disease (Opazo et al., 2002;
Haeffner et al., 2005; Nelson and Alkon, 2005; Puglielli et al., 2005;
Smith et al., 2006).
CHOLESTEROL MODULATION OF Aβ GENERATION, AGGREGATION, AND
CELL TOXICITY
The majority of in vivo data provide support for an involvement
of cholesterol in Aβ generation (Sparks et al., 1994; Bodovitz and
Klein, 1996; Bouillot et al., 1996; Lee et al., 1998; Simons et al.,
1998, 2001; Frears et al., 1999; Kojro et al., 2001; Wahrle et al.,
2002; Ehehalt et al., 2003; Vetrivel et al., 2004; Kalvodova et al.,
2005; Osenkowski et al., 2008). However, the impact of altering
plasma cholesterol on brain Aβ generation remains unclear. Ani-
mal studies report no correlation (Parkin et al., 1999) or inverse
correlation (Jin et al., 2004; Davis, 2008; Marquer et al., 2011)
between dietary or peripheral cholesterol and Aβ. Several rea-
sons can account for this disparity between studies, which include
genetic background, the transgenes present, age, gender, and/or
treatment conditions and environment. Another signiﬁcant rea-
son may be associated with the inherent selectivity of the BBB.
Cholesterol in the brain is synthesized de novo and it is unclear
to what extent peripheral or dietary cholesterol inﬂuences brain
cholesterol levels due to limited BBB penetration. Moreover, most
studies that examine the effects of high dietary cholesterol on
Aβ levels fail to measure brain cholesterol levels in the same
experimental settings. It is therefore uncertain if alteration of
brain Aβ levels is due to cholesterol changes in the brain or
some other indirect mechanism that is caused by the modula-
tion of peripheral cholesterol. Effects of Aβ generation under
in vivo paradigms and of cholesterol modulating genes on APP
processing/Aβ generation have been reviewed recently in detail
(Maulik et al., 2013). Results from these studies have shown strong
evidence that modulating cholesterol synthesis (Crameri et al.,
2006), intracellular trafﬁcking (Burns et al., 2003; Bryleva et al.,
2010; Kodam et al., 2010; Borbon and Erickson, 2011), uptake
(Bales et al., 1997, 1999; Holtzman et al., 2000; Irizarry et al., 2000;
Cao et al., 2006; Kim et al., 2009), and removal (Koldamova et al.,
2005; Wahrle et al., 2005, 2008) causally inﬂuence APP processing
and Aβ generation.
Cholesterol-rich lipid rafts may play a role in catalyzing the
aggregation of Aβ to its neurotoxic oligomeric state. Aβ isolated
from AD patients is associated with lipid rafts in a cholesterol-
dependent manner and reducing cholesterol levels results in less
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aggregated Aβ peptides (Schneider et al., 2006). Cholesterol is
likely to modulate Aβ aggregation through modifying raft com-
position. The ganglioside GM1, which is predominantly found
in the central nervous system, can bind Aβ peptides in lipid
rafts to form a complex that acts as an endogenous seed to
promote amyloid oligomerization, aggregation, and subsequent
ﬁbril formation (Choo-Smith et al., 1997; Kakio et al., 2002; Kim
et al., 2006; Okada et al., 2008; Matsuzaki et al., 2010). This has
been shown to be a primary mediator of oxidative stress on
plasma membrane (Zampagni et al., 2010). Some studies exam-
ining effects of cholesterol on Aβ toxicity in vitro provide evidence
that decreasing cholesterol, sialic acid, and ganglioside synthe-
sis is protective to PC12 cells, while increasing cholesterol levels
lead to increased Aβ neurotoxicity (Wang et al., 2001; Lin et al.,
2008). Interestingly, it has been observed that sustained ROS
production is associated with Aβ toxicity when exogenous choles-
terol is increased (Ferrera et al., 2008). Other studies disagree
with these results. PC12 cells and cultured neurons with high
cholesterol levels in the membrane are resistant to Aβ toxicity,
while low cholesterol levels increase their susceptibility (Zhou
and Richardson, 1996; Yip et al., 2001; Arispe and Doh, 2002;
Sponne et al., 2004). These divergent results suggest a dynamic
yet intricate correlation between cholesterol and Aβ peptide,
such that cholesterol’s inﬂuence on physical properties of lipid
rafts can modulate Aβ binding and aggregation to affect cell
viability.
METAL MODULATION OF Aβ DEGRADATION
The over-production of toxic Aβ is only one side of the equation
that contributes to senile plaque production and AD pathology,
with the other possible side, less frequently studied but equally
important, involving a fault in the degradation and clearance reg-
ulatory pathways of Aβ (reviewed in Carson and Turner, 2002;
Ling et al., 2003). Three proteases in the brain most frequently
studied in Aβ degradation, are insulin-degrading enzyme (IDE),
neprilysin (NEP), and plasmin. Of these three proteases, IDE and
NEP are members of the zinc metallopeptidase family of proteins
that have a zinc binding domain with common sequence homol-
ogy that can be potentially altered with aberrant zinc metabolism
(Vekrellis et al., 2000; Fan et al., 2009). Additionally, metal binding
ligands of both enzymes are oxidatively modiﬁed in the AD brain
by various ROS, such as hydroxyl radicals and products of ROS,
such as 4-hydroxy-2-nonenal (Wang et al., 2003; Caccamo et al.,
2005; Shinall et al., 2005). These data suggest that the generation
of ROS, perhaps as a product of metal:Aβ redox cycling, may serve
to inactivate proteases involved in Aβ degradation. Conversion of
plasminogen to plasmin involves cleavage from either tissue-type
(tPA) or urokinase-type plasminogen activator (Ledesma et al.,
2003). Inhibition by tPA cleavage of plasminogen is again caused
by increased redox cycling and production of ROS in the pres-
ence of copper/ascorbate (Lind et al., 1993). Plasmin itself may
also be regulated by site-speciﬁc oxidation; in particular, modiﬁ-
cation of the histidine molecule that resides in its active site (Lind
et al., 1993). Lastly, Aβ is a substrate for matrix metalloproteinase
(MMP), and plasmin has been shown to activate MMP2 degrada-
tion of Aβ, a process that is inhibited in the presence of zinc but
not copper (Crouch et al., 2009).
CHOLESTEROL MODULATION OF Aβ DEGRADATION
A number of recent studies have shown that cholesterol may be
involved in Aβ clearance by regulating Aβ degrading enzymes.
After synthesis, IDE is transported via the secretory pathway
to the cell membrane where it either remains or is secreted.
Given that a subset of IDE is localized in lipid rafts (Bulloj
et al., 2008), it is possible that cholesterol levels or distribu-
tion can regulate the transport and release of this protease to
inﬂuence Aβ degradation. Similar to IDE, the mature form of
NEP also associates with lipid rafts (Sato et al., 2012). Contra-
dictorily, targeting NEP chimeric proteins to lipid rafts fails to
efﬁciently degrade Aβ in this fraction (Hama et al., 2004). It
is of note that plasmin is also a raft protein (Ledesma et al.,
2003). Mice deﬁcient in seladin-1, which is required for choles-
terol synthesis, present disorganized rafts and impaired plas-
min function (Crameri et al., 2006; Stefani and Liguri, 2009).
These evidence supports the notion that cholesterol, possibly
through raft maintenance, is required for plasmin degradation
of Aβ.
APOE ASSOCIATION WITH METAL AND CHOLESTEROL ON ITS ROLE OF
Aβ CLEARANCE
There is strong evidence thatApoEplays a central, if not direct, role
in the pathogenesis of AD. The human APOE gene exists as three
polymorphic alleles (ε2, ε3, and ε4), and individuals possessing
the ε4 allele are at highest risk of developing AD (Bales et al., 2009;
Reiman et al., 2009; Castellano et al., 2011). ApoE is well known
for its involvement in the transportation of cholesterol. Together
with a multitude of other apolipoproteins, lipoprotein receptors,
and lipid transporters, ApoE controls cholesterol homeostasis in
the brain (brain cholesterol homeostasis reviewed in Hung et al.,
2013). Studies in human and transgenic mice demonstrate an iso-
form dependent (ε4 > ε3 > ε2) accumulation of Aβ levels and
amyloid plaque load.
Currently, there is no clear evidence that ApoE affects APP
processing and Aβ production in vitro and in vivo (Biere et al.,
1995; Cedazo-Minguez et al., 2001; Irizarry et al., 2004). How-
ever, ApoE appears to play an important role in Aβ clearance
through several possible mechanisms. In vitro studies with
neuronal cells have shown that lipidated ApoE binds to sol-
uble Aβ in an isoform-dependent manner (ε2 > ε3 > ε4)
and is internalized into various brain cells for degradation
by receptor-mediated endocytosis (Beffert et al., 1998, 1999;
Yang et al., 1999; Cole and Ard, 2000; Yamauchi et al., 2000,
2002). ApoE may also facilitate removal of Aβ from the brain
through the BBB (Cirrito et al., 2005; Zlokovic, 2008). ApoE
may be able to facilitate the cellular degradation of Aβ in vitro,
however, the mechanism and whether it is isoform-speciﬁc
still requires clariﬁcation (Crameri et al., 2006; Bryleva et al.,
2010).
There are very limited studies investigating metal interaction
with ApoE and its relationship with APP or Aβ. ApoE protein
binds copper, iron, and zinc, suggesting thatApoEhas the ability to
sequestermetals. Thismay underlie its isoform-dependent antiox-
idant activity (ε2> ε3> ε4;Miyata and Smith,1996). Interestingly,
ApoE4 contains a cysteine to arginine substitution at positions 112
and158. Since cysteine is believed tobe involved in transitionmetal
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binding, reduced afﬁnity of ApoE4 to metal may therefore relate
to diminished antioxidant effects of the ApoE4 allele (Moir et al.,
1999).
ATP binding cassette transporter A1 (ABCA1) is a cell sur-
facemembrane protein that promotes efﬂux of cellular cholesterol
to acceptor molecules, including ApoE and ApoA1. The ApoE4
isoform has been found to reduce ABCA1-mediated cholesterol
efﬂux in astrocytes and neurons in vitro (Michikawa et al., 2000;
Gong et al., 2007). Studies involving ABCA1-deﬁcient mice show
poor lipidation with decreased levels of ApoE (70–80% reduc-
tion) and a concurrent increase in amyloid plaque burden (Wahrle
et al., 2004, 2005; Hirsch-Reinshagen et al., 2005; Koldamova
et al., 2005). Conversely, ABCA1 overexpression in mice result
in increased lipidation and ApoE levels, and decreased amyloid
plaque formation (Wahrle et al., 2008). Interestingly, both ApoE
and ABCA1 can be modulated by transcription factor liver-X-
receptors (LXRs), which may be a key regulator in brain lipid
homeostasis. Indeed, deﬁciencies in LXRα and/or β augment AD
pathology (Zelcer et al., 2007), whereas treating AD mice with
LXR agonists, including Bexarotene, result in reduced amyloid
plaque burden and improved cognitive function (Eckert et al.,
2007; Riddell et al., 2007; Vanmierlo et al., 2011; Cramer et al.,
2012).
TWO SIDES OF THE SAME COIN: POSSIBLE CROSSTALK
BETWEEN METALS AND CHOLESTEROL IN APP/Aβ
METABOLISM
Independently, there are large bodies of research detailing the
inﬂuence of metals or cholesterol on the development, progres-
sion, andpathogenesis of AD.However, there are limited studies on
the relationship between metals and cholesterol in AD pathology.
The review thus far gives an overview of the impact of either met-
als or cholesterol on the amyloidogenic and non-amyloidogenic
processing pathways of APP. Interestingly, there are many overlaps
between these two factors impacting various processes in both of
these pathways. The reviewwill now examine interactions between
metals and cholesterol with APP and Aβ.
Epidemiological studies have shown that dietary intake of
trans- and saturated fats lead to an unfavorable cholesterol proﬁle
in AD patients and may associate with cognitive decline (Morris
et al., 2003, 2004). A follow-up study indicates that higher copper
intake is associated with an accelerated rate of cognitive decline
and that the copper-dependent acceleration is lost in individuals
whodid not consume a high fat diet (Morris et al., 2006). In animal
studies, cholesterol-fed rabbits have exacerbated neurodegenera-
tion following consumption of trace amounts of copper (Sparks
and Schreurs, 2003). Lowering cholesterol levels in patients by
atorvastatin (a cholesterol lowering drug which inhibits HMGCR)
saw an increase in circulating ceruloplasmin levels (Sparks et al.,
2005), a ferroxidase involved in iron homeostasis and due to its
role as a plasma copper transporter, a surrogate marker of plasma
copper status. Interestingly, like copper, increased dietary choles-
terol leads to dysregulation of iron regulatory proteins in rabbits
and also iron accumulation in Aβ plaques (Ghribi et al., 2006).
An epidemiological study in a large cohort of adults found that
abnormally high dietary cholesterol and iron intakes increase the
risk of AD (Mainous et al., 2005).
Based on evidence from the studies reviewed in Sections “Met-
als and APP” and “Cholesterol and APP,” it may be inferred
that both metals and cholesterol are able to modulate APP
metabolism/expression through a process that remains to be elu-
cidated. Conversely, APP itself can regulate metal and cholesterol
homeostasis. Therefore, APP may be envisioned as a key regulator
linking both metal and cholesterol homeostasis, whereby unregu-
latedmetal or cholesterol leads to a downstream effect onAPP that
may ultimately cause an erroneous outcome in collateral systems.
One way in which copper, iron, and zinc can impact on
the pathology of AD stems from their relative ease in switching
oxidation states. This property makes it particularly useful for
enzymatic reactions requiring electron transfer (Waldron et al.,
2009). Metals can affect APP processing (Figure 1B) and Aβ
degradation (Figure 2) by altering catalytic properties of sec-
retases, which are metalloproteins (reviewed in Sections “Metal
Modulation of APP Processing Enzymes” and “Metal Modulation
of Aβ Degradation”). Cholesterol, on the other hand inﬂuences
APP processing (Figure 1B) and Aβ degradation (Figure 2)
through lipid raft association of substrates (APP and Aβ) and
enzymes (APP processing secretases and Aβ degrading proteases;
reviewed in sections “Cholesterol Modulation of APP Processing”
and “Cholesterol Modulation of Aβ Degradation”). Cholesterol
inﬂuences both the quantity and quality of the lipid raft domains.
For example, cholesterol can modulate the order of raft compo-
nents to provide the right environment for protein binding or
function. In other words, metals modulate APP processing and
Aβ degradation through the mechanistic action of the enzyme,
whereas cholesterol does so throughmanipulation of the environ-
ment and presentation of the substrate and/or enzyme on the
plasma membrane. Although this relationship between metals
and cholesterol may not be mutually exclusive, a fault in either
system may still lead to similar pathological outcomes in AD
(Figure 2).
More recently, copper has been observed to directly inﬂuence
the lipid raft protein, ﬂotillin-2 (Hung et al., 2009). Flotillin-2
interacts with APP at the cell surface (Schneider et al., 2008). The
endocytosis of APP to BACE1-rich endosomes, required for β-
cleavage of APP, is sensitive to ﬂotillin-2 depletion (Ehehalt et al.,
2003; Schneider et al., 2008). Analogous to cholesterol deple-
tion, elevated copper reduces ﬂotillin-2 association with lipid
rafts, thereby reducing endocytosis of APP and attenuating Aβ
production (Hung et al., 2009).
Interestingly, both metals and cholesterol are able to catalyze
the oligomeric aggregation of Aβ required for its cytotoxic effect
(see “Metal Modulation of Aβ Generation, Aggregation, and Cell
Toxicity”and“CholesterolModulationofAβGeneration,Aggrega-
tion, and Cell Toxicity”; Figure 2). The mechanism of aggregated
Aβ toxicity is still a matter of debate. However, elevation of ROS
in both metal:Aβ or GM1:Aβ complexes suggests an involvement
of metal as a mechanistic partner to redox cycle and generating
harmful ROS products from both metal- and cholesterol-based
aggregation of Aβ in vitro.
Oxysterols also play an important role in the regulation of
cholesterol in the brain and the body. In the brain, oxysterols
are produced by conversion of cholesterol to the oxidized species,
24OHC, by the enzyme 24S-hydroxylase. 24OHC represents
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FIGURE 2 | Metals and cholesterol implicated in Aβ processing and
neurotoxicity. (A) Upon cleavage from APP, both metal and cholesterol
bind to Aβ monomers promoting oligomerization of the peptide into
multiple types of Aβ aggregates. These aggregates are either present within
the extracellular space or bound to the surface of the plasma membrane
(red arrows). Select Aβ aggregates are neurotoxic through multiple
mechanisms such as their ability to generate reactive oxygen species (ROS)
and may have implications in AD associated neuropathology. The ability of
copper, iron, and cholesterol to promote redox cycling are acutely involved
in the cytotoxicity caused by aggregated Aβ. (B) As with APP processing
enzymes (Figure 1B), proteases that degrade Aβ, such as neprilysin (NEP)
and insulin degrading enzyme (IDE) are dependent on metals for their
catalytic activity. These proteases are also lipid raft associated and
modulated by cholesterol levels in these domains. (C) Lipidated ApoE,
produced mainly by astrocytes and microglia, binds soluble Aβ and
facilitates its degradation through receptor-mediated endocytosis within
neurons and microglial or clearance from the brain through the blood–brain
barrier (BBB; blue arrows). Lipidated ApoE regulation is modulated by
nuclear transcription factors LXRs. LXR heterodimerizes with RXR to
transcriptionally regulate ABCA1 and ApoE. ABCA1 exports cellular
cholesterol and phospholipids that in turn lipidate ApoE to form HDL-like
particles (green arrows). These HDL-like particles are required for the
clearance of Aβ. Intriguingly, the LXR agonist, oxysterols is elevated in the
AD brain and may result from cholesterol oxidation by metals and
24S-hydroxylase. Evidence implies that the involvement of metal and
cholesterol in the Aβ processing pathway is not just deleterious (as in A)
but may also have importance in degradation and clearance of this
potentially harmful peptide (B,C).
one of the main forms of cholesterol that can be trafﬁcked
out of the brain to the circulatory system by its permeabil-
ity across the BBB (Bjorkhem et al., 1998; Lund et al., 1999;
Ehehalt et al., 2003; Lutjohann and von Bergmann, 2003; Schnei-
der et al., 2008). Interestingly, APP has been shown recently
to regulate 24S-hydroxylase levels (Pierrot et al., 2013). Oxys-
terols are agonists of LXRs, the latter of which form heterodimer
complexes with retinoid x receptor (RXR) to transcription-
ally regulate the production of a number of genes involved
in the cholesterol regulatory pathway including ApoE, ABCA1,
ABCG1, and SREBP1 (Bjorkhem, 2013). Through this path-
way, oxysterols are able to regulate cholesterol efﬂux from cells
via LXRs (Figure 2). In the progression of AD, levels of oxys-
terols are elevated, possibly due to effects of 24S-hydroxylase
and non-enzymatic oxidation of cholesterol caused by elevated
metal levels (Iuliano, 2011). This may be a way in which
the brain is utilizing a feedback mechanism to clear excess
cholesterol and Aβ peptides. Therefore, it is not surprising
that elevated LXR-induced expression of ApoE4 (with defec-
tive Aβ and cholesterol clearance) compared to ApoE2, results
in continued accumulation of neuritic plaques. The pathol-
ogy of the disease continues to progress in a positive feed-
back loop of increased cholesterol, ROS, and Aβ generation
(Figure 2).
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CONCLUSION
Metal and cholesterol are intrinsically linked to the pathogenesis
of AD. Despite large bodies of research examining the abnormal-
ities of metals and cholesterol in AD, the reciprocal inﬂuence
of these two factors in the cause and progression of the disease
remains to be elucidated. This review presents an overview of how
metals and cholesterol independently impact upon the amyloido-
genic and non-amyloidogenic processing of APP. It highlights the
close and complex relationship between metals and cholesterol in
the maintenance of normal brain physiology and the progression
of AD pathology, with respect to interactions with AD-related
proteins APP and Aβ. In the scheme of APP processing and Aβ
metabolism, a disturbance to one homeostatic system may likely
lead to a direct or indirect dysregulation of the other, although
some of its molecular actions are mutually exclusive, the even-
tual deleterious outcome is the same. Continued research into
metal or cholesterol inﬂuences on AD pathology must take careful
consideration of the other factor, given that they are intrinsi-
cally linked. For example, the study of an inﬂuential effect metals
has on ApoE should always take into account its lipidation sta-
tus, which affects its conformation and activity. Conversely, the
study of Aβ aggregation in lipid rafts should consider the role
metals play in the generation of ROS products and subsequent
cell toxicity. Further research is needed to investigate molecular
mechanisms that link metals and cholesterol with various players
involved in AD pathogenesis. This knowledge is critical for future
design and implementation of effective therapeutic strategies to
treat AD.
ACKNOWLEDGMENTS
This work was supported by funding from the National Health
and Medical Research Council of Australia (to Ashley I. Bush and
James A. Duce), Australian Research Council (to Ashley I. Bush),
CooperativeResearchCentre forMentalHealth (toAshley I. Bush),
Alzheimer’s Research UK (to James A. Duce), the Addi and Cassi
Fund (to Ashley I. Bush and Ya Hui Hung), Perpetual Trustees
[Harry Secomb Foundation and Payne L and Heather Medical
Research Charitable Foundation (to Ashley I. Bush)], The Florey
Institute of Neuroscience and Mental Health acknowledges the
strong support from the Victorian Government and in particular
the funding from the Operational Infrastructure Support Grant.
REFERENCES
Acevedo, K. M., Hung, Y. H., Dalziel, A. H., Li, Q. X., Laughton, K.,Wikhe, K., et al.
(2011). Copper promotes the trafﬁcking of the amyloid precursor protein. J. Biol.
Chem. 286, 8252–8262. doi: 10.1074/jbc.M110.128512
Ali, F. E., Separovic, F., Barrow, C. J., Cherny, R. A., Fraser, F., Bush, A. I., et al.
(2005). Methionine regulates copper/hydrogen peroxide oxidation products of
Abeta. J. Pept. Sci. 11, 353–360. doi: 10.1002/psc.626
Angeletti, B., Waldron, K. J., Freeman, K. B., Bawagan, H., Hussain, I., Miller, C. C.,
et al. (2005). BACE1 cytoplasmic domain interacts with the copper chaperone for
superoxide dismutase-1 and binds copper. J. Biol. Chem. 280, 17930–17937. doi:
10.1074/jbc.M412034200
Area-Gomez, E., Del Carmen Lara Castillo, M., Tambini, M. D., Guardia-
Laguarta, C., De Groof, A. J., Madra, M., et al. (2012). Upregulated function
of mitochondria-associated ER membranes in Alzheimer disease. EMBO J. 31,
4106–4123. doi: 10.1038/emboj.2012.202
Arispe, N., and Doh, M. (2002). Plasma membrane cholesterol controls the cyto-
toxicity of Alzheimer’s disease AbetaP (1-40) and (1-42) peptides. FASEB J. 16,
1526–1536. doi: 10.1096/fj.02-0829com
Armendariz, A. D., Gonzalez, M., Loguinov, A. V., and Vulpe, C. D. (2004). Gene
expression proﬁling in chronic copper overload reveals upregulation of Prnp and
App. Physiol. Genomics 20, 45–54. doi: 10.1152/physiolgenomics.00196.2003
Atwood, C. S., Moir, R. D., Huang, X., Scarpa, R. C., Bacarra, N. M., Romano, D. M.,
et al. (1998). Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by
conditions representing physiological acidosis. J. Biol. Chem. 273, 12817–12826.
doi: 10.1074/jbc.273.21.12817
Atwood, C. S., Perry, G., Zeng, H., Kato, Y., Jones, W. D., Ling, K. Q., et al.
(2004). Copper mediates dityrosine cross-linking of Alzheimer’s amyloid-beta.
Biochemistry 43, 560–568. doi: 10.1021/bi0358824
Atwood, C. S., Scarpa, R. C., Huang, X., Moir, R. D., Jones, W. D., Fairlie, D.
P., et al. (2000). Characterization of copper interactions with Alzheimer amy-
loid beta peptides: identiﬁcation of an attomolar-afﬁnity copper binding site on
amyloid beta1-42. J. Neurochem. 75, 1219–1233. doi: 10.1046/j.1471-4159.2000.
0751219.x
Bales, K. R., Liu, F.,Wu, S., Lin, S., Koger, D., Delong, C., et al. (2009). HumanAPOE
isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic
mice. J. Neurosci. 29, 6771–6779. doi: 10.1523/JNEUROSCI.0887-09.2009
Bales, K. R., Verina, T., Cummins, D. J., Du, Y., Dodel, R. C., Saura, J., et al.
(1999). Apolipoprotein E is essential for amyloid deposition in the APP(V717F)
transgenic mouse model of Alzheimer’s disease. Proc. Natl. Acad. Sci. U.S.A. 96,
15233–15238. doi: 10.1073/pnas.96.26.15233
Bales, K. R., Verina, T., Dodel, R. C., Du, Y., Altstiel, L., Bender, M., et al. (1997).
Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition.
Nat. Genet. 17, 263–264. doi: 10.1038/ng1197-263
Baltes, C., Princz-Kranz, F., Rudin,M., andMueggler, T. (2011). Detecting amyloid-
beta plaques in Alzheimer’s disease. Methods Mol. Biol. 711, 511–533. doi:
10.1007/978-1-61737-992-5_26
Barnham, K. J., Haeffner, F., Ciccotosto, G. D., Curtain, C. C., Tew, D., Mavros,
C., et al. (2004). Tyrosine gated electron transfer is key to the toxic mechanism
of Alzheimer’s disease beta-amyloid. FASEB J. 18, 1427–1429. doi: 10.1096/fj.04-
1890fje
Barnham, K. J.,Mckinstry,W. J.,Multhaup, G., Galatis, D.,Morton, C. J., Curtain, C.
C., et al. (2003). Structure of the Alzheimer’s disease amyloid precursor protein
copper binding domain. A regulator of neuronal copper homeostasis. J. Biol.
Chem. 278, 17401–17407. doi: 10.1074/jbc.M300629200
Barrett, P. J., Song, Y., Van Horn, W. D., Hustedt, E. J., Schafer, J. M.,
Hadziselimovic, A., et al. (2012). The amyloid precursor protein has a ﬂexi-
ble transmembrane domain and binds cholesterol. Science 336, 1168–1171. doi:
10.1126/science.1219988
Bayer, T. A., Schafer, S., Simons,A., Kemmling,A., Kamer, T., Tepest, R., et al. (2003).
Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid
Abeta production in APP23 transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 100,
14187–14192. doi: 10.1073/pnas.2332818100
Beel, A. J., Sakakura, M., Barrett, P. J., and Sanders, C. R. (2010). Direct binding of
cholesterol to the amyloid precursor protein: an important interaction in lipid-
Alzheimer’s disease relationships? Biochim. Biophys. Acta 1801, 975–982. doi:
10.1016/j.bbalip.2010.03.008
Beffert, U., Aumont, N., Dea, D., Lussier-Cacan, S., Davignon, J., and Poirier,
J. (1998). Beta-amyloid peptides increase the binding and internalization of
apolipoprotein E to hippocampal neurons. J. Neurochem. 70, 1458–1466. doi:
10.1046/j.1471-4159.1998.70041458.x
Beffert, U., Aumont, N., Dea, D., Lussier-Cacan, S., Davignon, J., and Poirier, J.
(1999). Apolipoprotein E isoform-speciﬁc reduction of extracellular amyloid in
neuronal cultures. Brain Res. Mol. Brain Res. 68, 181–185. doi: 10.1016/S0169-
328X(99)00073-X
Bellingham, S. A., Ciccotosto, G. D., Needham, B. E., Fodero, L. R., White, A.
R., Masters, C. L., et al. (2004a). Gene knockout of amyloid precursor protein
and amyloid precursor-like protein-2 increases cellular copper levels in primary
mouse cortical neurons and embryonic ﬁbroblasts. J. Neurochem. 91, 423–428.
doi: 10.1111/j.1471-4159.2004.02731.x
Bellingham, S. A., Lahiri, D. K., Maloney, B., La Fontaine, S., Multhaup, G.,
and Camakaris, J. (2004b). Copper depletion down-regulates expression of the
Alzheimer’s disease amyloid-beta precursor protein gene. J. Biol. Chem. 279,
20378–20386. doi: 10.1074/jbc.M400805200
Bertram, L., Mcqueen, M. B., Mullin, K., Blacker, D., and Tanzi, R. E. (2007).
Systematic meta-analyses of Alzheimer disease genetic association studies: the
AlzGene database. Nat. Genet. 39, 17–23. doi: 10.1038/ng1934
Frontiers in Aging Neuroscience www.frontiersin.org May 2014 | Volume 6 | Article 91 | 10
Wong et al. Metals and cholesterol in AD
Bertram, L., and Tanzi, R. E. (2005). The genetic epidemiology of neurodegenerative
disease. J. Clin. Invest. 115, 1449–1457. doi: 10.1172/JCI24761
Biere, A. L., Ostaszewski, B., Zhao, H., Gillespie, S., Younkin, S. G., and Selkoe,
D. J. (1995). Co-expression of beta-amyloid precursor protein (betaAPP) and
apolipoprotein E in cell culture: analysis of betaAPP processing. Neurobiol. Dis.
2, 177–187. doi: 10.1006/nbdi.1995.0019.
Bjorkhem, I. (2013). Five decades with oxysterols. Biochimie 95, 448–454. doi:
10.1016/j.biochi.2012.02.029
Bjorkhem, I., Lutjohann, D., Diczfalusy, U., Stahle, L., Ahlborg, G., and
Wahren, J. (1998). Cholesterol homeostasis in human brain: turnover of 24S-
hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in
the circulation. J. Lipid Res. 39, 1594–1600.
Blacker, M., Noe, M. C., Carty, T. J., Goodyer, C. G., and Leblanc, A.
C. (2002). Effect of tumor necrosis factor-alpha converting enzyme (TACE)
and metalloprotease inhibitor on amyloid precursor protein metabolism in
human neurons. J. Neurochem. 83, 1349–1357. doi: 10.1046/j.1471-4159.2002.
01228.x
Bodovitz, S., and Klein, W. L. (1996). Cholesterol modulates alpha-secretase
cleavage of amyloid precursor protein. J. Biol. Chem. 271, 4436–4440. doi:
10.1074/jbc.271.8.4436
Borbon, I. A., and Erickson, R. P. (2011). Interactions of Npc1 and amyloid accu-
mulation/deposition in the APP/PS1 mouse model of Alzheimer’s. J. Appl. Genet.
52, 213–218. doi: 10.1007/s13353-010-0021-1
Bouillot, C., Prochiantz, A., Rougon, G., and Allinquant, B. (1996). Axonal
amyloid precursor protein expressed by neurons in vitro is present in a mem-
brane fraction with caveolae-like properties. J. Biol. Chem. 271, 7640–7644. doi:
10.1074/jbc.271.13.7640
Brown, M. S., and Goldstein, J. L. (1999). A proteolytic pathway that controls the
cholesterol content of membranes, cells, and blood. Proc. Natl. Acad. Sci. U.S.A.
96, 11041–11048. doi: 10.1073/pnas.96.20.11041
Bryleva, E. Y., Rogers, M. A., Chang, C. C., Buen, F., Harris, B. T., Rousse-
let, E., et al. (2010). ACAT1 gene ablation increases 24(S)-hydroxycholesterol
content in the brain and ameliorates amyloid pathology in mice with AD.
Proc. Natl. Acad. Sci. U.S.A. 107, 3081–3086. doi: 10.1073/pnas.09138
28107
Buckley, C. A., Rouhani, F. N., Kaler, M., Adamik, B., Hawari, F. I., and Levine,
S. J. (2005). Amino-terminal TACE prodomain attenuates TNFR2 cleavage inde-
pendently of the cysteine switch. Am. J. Physiol. Lung Cell. Mol. Physiol. 288,
L1132–L1138. doi: 10.1152/ajplung.00429.2004
Bulloj, A., Leal, M. C., Surace, E. I., Zhang, X., Xu, H., Ledesma, M. D., et al.
(2008). Detergent resistantmembrane-associated IDE inbrain tissue and cultured
cells: relevance to Abeta and insulin degradation. Mol. Neurodegener. 3, 22. doi:
10.1186/1750-1326-3-22
Burns, M., Gaynor, K., Olm, V., Mercken, M., Lafrancois, J., Wang, L., et al. (2003).
Presenilin redistribution associated with aberrant cholesterol transport enhances
beta-amyloid production in vivo. J. Neurosci. 23, 5645–5649.
Bush, A. I., Multhaup, G., Moir, R. D., Williamson, T. G., Small, D. H., Rumble,
B., et al. (1993). A novel zinc(II) binding site modulates the function of the
beta A4 amyloid protein precursor of Alzheimer’s disease. J. Biol. Chem. 268,
16109–16112.
Bush, A. I., Pettingell, W. H. Jr., De Paradis, M., Tanzi, R. E., and Wasco, W.
(1994a). The amyloid beta-protein precursor and its mammalian homologues.
Evidence for a zinc-modulated heparin-binding superfamily. J. Biol. Chem. 269,
26618–26621.
Bush,A. I., Pettingell,W. H. Jr., Paradis,M. D., and Tanzi, R. E. (1994b). Modulation
of A beta adhesiveness and secretase site cleavage by zinc. J. Biol. Chem. 269,
12152–12158.
Bush, A. I., Pettingell, W. H., Multhaup, G., d Paradis, M., Vonsattel, J. P., Gusella,
J. F., et al. (1994c). Rapid induction of Alzheimer A beta amyloid formation by
zinc. Science 265, 1464–1467. doi: 10.1126/science.8073293
Buxbaum, J. D., Liu, K. N., Luo, Y., Slack, J. L., Stocking, K. L., Peschon, J. J., et al.
(1998). Evidence that tumor necrosis factor alpha converting enzyme is involved
in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor.
J. Biol. Chem. 273, 27765–27767. doi: 10.1074/jbc.273.43.27765
Caccamo, A., Oddo, S., Sugarman, M. C., Akbari, Y., and Laferla, F. M.
(2005). Age- and region-dependent alterations in Abeta-degrading enzymes:
implications for Abeta-induced disorders. Neurobiol. Aging 26, 645–654. doi:
10.1016/j.neurobiolaging.2004.06.013
Cao, D., Fukuchi, K., Wan, H., Kim, H., and Li, L. (2006). Lack of LDL receptor
aggravates learning deﬁcits and amyloid deposits in Alzheimer transgenic mice.
Neurobiol. Aging 27, 1632–1643. doi: 10.1016/j.neurobiolaging.2005.09.011
Carson, J. A., and Turner, A. J. (2002). Beta-amyloid catabolism: roles for neprilysin
(NEP) and other metallopeptidases? J. Neurochem. 81, 1–8. doi: 10.1046/j.1471-
4159.2002.00855.x
Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., Demattos, R. B., Patterson, B.
W., et al. (2011). Human apoE isoforms differentially regulate brain amyloid-beta
peptide clearance. Sci. Transl. Med. 3, 89ra57. doi: 10.1126/scitranslmed.3002156
Cedazo-Minguez, A., Wiehager, B., Winblad, B., Huttinger, M., and Cow-
burn, R. F. (2001). Effects of apolipoprotein E (apoE) isoforms, beta-amyloid
(Abeta) and apoE/Abeta complexes on protein kinase C-alpha (PKC-alpha)
translocation and amyloid precursor protein (APP) processing in human SH-
SY5Y neuroblastoma cells and ﬁbroblasts. Neurochem. Int. 38, 615–625. doi:
10.1016/S0197-0186(00)00128-5
Chen, J. H., Lin, K. P., and Chen, Y. C. (2009). Risk factors for dementia. J. Formos.
Med. Assoc. 108, 754–764. doi: 10.1016/S0929-6646(09)60402-2
Cho, H. H., Cahill, C. M., Vanderburg, C. R., Scherzer, C. R., Wang, B., Huang, X.,
et al. (2010). Selective translational control of the Alzheimer amyloid precursor
protein transcript by iron regulatory protein-1. J. Biol. Chem. 285, 31217–31232.
doi: 10.1074/jbc.M110.149161
Choo-Smith, L. P., Garzon-Rodriguez, W., Glabe, C. G., and Surewicz, W. K.
(1997). Acceleration of amyloid ﬁbril formation by speciﬁc binding of Abeta-
(1-40) peptide to ganglioside-containing membrane vesicles. J. Biol. Chem. 272,
22987–22990. doi: 10.1074/jbc.272.37.22987
Ciccotosto, G. D., Tew, D., Curtain, C. C., Smith, D., Carrington, D., Masters, C. L.,
et al. (2004). Enhanced toxicity and cellular binding of a modiﬁed amyloid beta
peptidewith amethionine to valine substitution. J. Biol. Chem. 279, 42528–42534.
doi: 10.1074/jbc.M406465200
Cirrito, J. R., Deane, R., Fagan, A. M., Spinner, M. L., Parsadanian, M., Finn, M.
B., et al. (2005). P-glycoprotein deﬁciency at the blood–brain barrier increases
amyloid-beta deposition in an Alzheimer disease mouse model. J. Clin. Invest.
115, 3285–3290. doi: 10.1172/JCI25247
Ciuculescu, E. D.,Mekmouche,Y., and Faller, P. (2005). Metal-binding properties of
the peptide APP170-188: a model of the ZnII-binding site of amyloid precursor
protein (APP). Chemistry 11, 903–909. doi: 10.1002/chem.200400786
Cleary, J. P.,Walsh, D.M.,Hofmeister, J. J., Shankar, G.M., Kuskowski,M.A., Selkoe,
D. J., et al. (2005). Natural oligomers of the amyloid-beta protein speciﬁcally
disrupt cognitive function. Nat. Neurosci. 8, 79–84. doi: 10.1038/nn1372
Cole, G. M., and Ard, M. D. (2000). Inﬂuence of lipoproteins on microglial degra-
dation of Alzheimer’s amyloid beta-protein. Microsc. Res. Tech. 50, 316–324. doi:
10.1002/1097-0029(20000815)50:4<316::AID-JEMT11>3.0.CO;2-E
Cole, T. B., Wenzel, H. J., Kafer, K. E., Schwartzkroin, P. A., and Palmiter, R. D.
(1999). Elimination of zinc from synaptic vesicles in the intact mouse brain by
disruption of the ZnT3 gene. Proc. Natl. Acad. Sci. U.S.A. 96, 1716–1721. doi:
10.1073/pnas.96.4.1716
Collingwood, J. F., Mikhaylova, A., Davidson, M., Batich, C., Streit, W. J., Terry,
J., et al. (2005). In situ characterization and mapping of iron compounds in
Alzheimer’s disease tissue. J. Alzheimers Dis. 7, 267–272.
Connor, J. R., Snyder, B. S., Beard, J. L., Fine, R. E., and Mufson, E. J. (1992).
Regional distribution of iron and iron-regulatory proteins in the brain in aging
andAlzheimer’s disease. J. Neurosci. Res. 31, 327–335. doi: 10.1002/jnr.490310214
Coon, K. D., Myers, A. J., Craig, D. W., Webster, J. A., Pearson, J. V., Lince, D. H.,
et al. (2007). A high-density whole-genome association study reveals that APOE
is themajor susceptibility gene for sporadic late-onset Alzheimer’s disease. J. Clin.
Psychiatry 68, 613–618. doi: 10.4088/JCP.v68n0419
Cramer, P. E., Cirrito, J. R., Wesson, D. W., Lee, C. Y., Karlo, J. C., Zinn, A. E.,
et al. (2012). ApoE-directed therapeutics rapidly clear beta-amyloid and reverse
deﬁcits in AD mouse models. Science 335, 1503–1506. doi: 10.1126/science.
1217697
Crameri, A., Biondi, E., Kuehnle, K., Lutjohann, D., Thelen, K. M., Perga,
S., et al. (2006). The role of seladin-1/DHCR24 in cholesterol biosynthesis,
APP processing and Abeta generation in vivo. EMBO J. 25, 432–443. doi:
10.1038/sj.emboj.7600938
Cross, J. B., Duca, J. S., Kaminski, J. J., and Madison, V. S. (2002). The active site
of a zinc-dependent metalloproteinase inﬂuences the computed pK(a) of ligands
coordinated to the catalytic zinc ion. J. Am. Chem. Soc. 124, 11004–11007. doi:
10.1021/ja0201810
Frontiers in Aging Neuroscience www.frontiersin.org May 2014 | Volume 6 | Article 91 | 11
Wong et al. Metals and cholesterol in AD
Crouch, P. J., Tew, D. J., Du, T., Nguyen, D. N., Caragounis, A., Filiz,
G., et al. (2009). Restored degradation of the Alzheimer’s amyloid-beta pep-
tide by targeting amyloid formation. J. Neurochem. 108, 1198–1207. doi:
10.1111/j.1471-4159.2009.05870.x
Cummings, J. L. (2004). Alzheimer’s disease. N. Engl. J. Med. 351, 56–67. doi:
10.1056/NEJMra040223
Curtain, C. C., Ali, F., Volitakis, I., Cherny, R. A., Norton, R. S., Beyreuther,
K., et al. (2001). Alzheimer’s disease amyloid-beta binds copper and zinc to
generate an allosterically ordered membrane-penetrating structure containing
superoxide dismutase-like subunits. J. Biol. Chem. 276, 20466–20473. doi:
10.1074/jbc.M100175200
Dahlgren, K. N., Manelli, A. M., Stine, W. B. Jr., Baker, L. K., Krafft, G. A.,
et al. (2002). Oligomeric and ﬁbrillar species of amyloid-beta peptides dif-
ferentially affect neuronal viability. J. Biol. Chem. 277, 32046–32053. doi:
10.1074/jbc.M201750200
Dahms, S. O., Konnig, I., Roeser, D., Guhrs, K. H., Mayer, M. C., Kaden, D.,
et al. (2012). Metal binding dictates conformation and function of the amy-
loid precursor protein (APP) E2 domain. J. Mol. Biol. 416, 438–452. doi:
10.1016/j.jmb.2011.12.057
Danielsson, J., Pierattelli, R., Banci, L., and Graslund, A. (2007). High-resolution
NMR studies of the zinc-binding site of the Alzheimer’s amyloid beta-peptide.
FEBS J. 274, 46–59. doi: 10.1111/j.1742-4658.2006.05563.x
Davis, C. D., Milne, D. B., and Nielsen, F. H. (2000). Changes in dietary zinc and
copper affect zinc-status indicators of postmenopausal women, notably, extracel-
lular superoxide dismutase and amyloid precursor proteins. Am. J. Clin. Nutr. 71,
781–788.
Davis,W. Jr. (2008). The cholesterol transport inhibitor U18666a regulates amyloid
precursor protein metabolism and trafﬁcking in N2aAPP “Swedish” cells. Curr.
Alzheimer Res. 5, 448–456. doi: 10.2174/156720508785908900
Delacourte, A., and Defossez, A. (1986). Alzheimer’s disease: tau proteins, the
promoting factors of microtubule assembly, are major components of paired
helical ﬁlaments. J. Neurol. Sci. 76, 173–186. doi: 10.1016/0022-510X(86)90167-X
Donovan, A., Lima, C. A., Pinkus, J. L., Pinkus, G. S., Zon, L. I., Robine, S., et al.
(2005). The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis.
Cell Metab. 1, 191–200. doi: 10.1016/j.cmet.2005.01.003
Duce, J. A., and Bush, A. I. (2010). Biological metals and Alzheimer’s disease:
implications for therapeutics and diagnostics. Prog. Neurobiol. 92, 1–18. doi:
10.1016/j.pneurobio.2010.04.003
Duce, J. A., Tsatsanis, A., Cater, M. A., James, S. A., Robb, E.,Wikhe, K., et al. (2010).
Iron-export ferroxidase activity of beta-amyloid precursor protein is inhibited
by zinc in Alzheimer’s disease. Cell 142, 857–867. doi: 10.1016/j.cell.2010.
08.014
Eckert, A., Hauptmann, S., Scherping, I., Meinhardt, J., Rhein, V., Drose, S., et al.
(2008). Oligomeric and ﬁbrillar species of beta-amyloid (A beta 42) both impair
mitochondrial function in P301L tau transgenic mice. J. Mol. Med. (Berl.) 86,
1255–1267. doi: 10.1007/s00109-008-0391-6
Eckert, G. P., Vardanian, L., Rebeck, G. W., and Burns, M. P. (2007). Regulation
of central nervous system cholesterol homeostasis by the liver X receptor agonist
TO-901317. Neurosci. Lett. 423, 47–52. doi: 10.1016/j.neulet.2007.05.063
Eckert, G. P., Wood, W. G., and Muller, W. E. (2010). Lipid membranes and
beta-amyloid: a harmful connection. Curr. Protein Pept. Sci 11, 319–325. doi:
10.2174/138920310791330668
Edbauer, D., Winkler, E., Regula, J. T., Pesold, B., Steiner, H., and Haass, C.
(2003). Reconstitution of gamma-secretase activity. Nat. Cell Biol. 5, 486–488.
doi: 10.1038/ncb960
Ehehalt, R., Keller, P., Haass, C., Thiele, C., and Simons, K. (2003). Amyloidogenic
processing of the Alzheimer beta-amyloid precursor protein depends on lipid
rafts. J. Cell Biol. 160, 113–123. doi: 10.1083/jcb.200207113
Faller, P., and Hureau, C. (2009). Bioinorganic chemistry of copper and zinc
ions coordinated to amyloid-beta peptide. Dalton Trans. 1080–1094. doi:
10.1039/b813398k
Fan, J., Donkin, J., andWellington, C. (2009). Greasing the wheels of Abeta clearance
in Alzheimer’s disease: the role of lipids and apolipoprotein E. Biofactors 35,
239–248. doi: 10.1002/biof.37
Farrer, L. A., Cupples, L. A., Haines, J. L., Hyman, B., Kukull,W. A.,Mayeux, R., et al.
(1997). Effects of age, sex, and ethnicity on the association between apolipopro-
tein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer
Disease Meta Analysis Consortium. JAMA 278, 1349–1356. doi: 10.1002/biof.37
Fenton, H. J. H. (1894). Oxidation of tartaric acid in presence of iron. J. Chem. Soc.
Trans. 65, 899–911. doi: 10.1039/ct8946500899
Ferrera, P., Mercado-Gomez, O., Silva-Aguilar, M., Valverde, M., and Arias, C.
(2008). Cholesterol potentiates beta-amyloid-induced toxicity in human neurob-
lastoma cells: involvement of oxidative stress. Neurochem. Res. 33, 1509–1517.
doi: 10.1007/s11064-008-9623-y
Frears, E. R., Stephens, D. J., Walters, C. E., Davies, H., and Austen, B. M. (1999).
The role of cholesterol in the biosynthesis of beta-amyloid. Neuroreport 10, 1699–
1705. doi: 10.1007/s11064-008-9623-y
Friedlich, A. L., Lee, J. Y., Van Groen, T., Cherny, R. A., Volitakis, I., Cole, T. B., et al.
(2004). Neuronal zinc exchange with the blood vessel wall promotes cerebral
amyloid angiopathy in an animal model of Alzheimer’s disease. J. Neurosci. 24,
3453–3459. doi: 10.1523/JNEUROSCI.0297-04.2004
Gaggelli, E., Grzonka, Z., Kozlowski, H., Migliorini, C., Molteni, E., Valensin, D.,
et al. (2008). Structural features of the Cu(II) complex with the rat Abeta(1-28)
fragment. Chem. Commun. (Camb.) 341–343. doi: 10.1523/JNEUROSCI.0297-
04.2004
Ganz, T. (2005). Cellular iron: ferroportin is the only way out. Cell Metab. 1,
155–157. doi: 10.1016/j.cmet.2005.02.005
Garai, K., Sengupta, P., Sahoo, B., and Maiti, S. (2006). Selective destabilization of
soluble amyloid beta oligomers by divalent metal ions. Biochem. Biophys. Res.
Commun. 345, 210–215. doi: 10.1016/j.bbrc.2006.04.056
Ghribi, O., Golovko, M. Y., Larsen, B., Schrag, M., and Murphy, E. J. (2006).
Deposition of iron and beta-amyloid plaques is associated with cortical cellular
damage in rabbits fed with long-term cholesterol-enriched diets. J. Neurochem.
99, 438–449. doi: 10.1111/j.1471-4159.2006.04079.x
Glenner,G.G., andWong,C.W. (1984a). Alzheimer’s disease andDown’s syndrome:
sharing of a unique cerebrovascular amyloid ﬁbril protein. Biochem. Biophys. Res.
Commun. 122, 1131–1135. doi: 10.1016/0006-291X(84)91209-9
Glenner, G. G., and Wong, C. W. (1984b). Alzheimer’s disease: initial report
of the puriﬁcation and characterization of a novel cerebrovascular amyloid
protein. Biochem. Biophys. Res. Commun. 120, 885–890. doi: 10.1016/S0006-
291X(84)80190-4
Gong, J. S., Morita, S. Y., Kobayashi, M., Handa, T., Fujita, S. C., Yanagisawa, K.,
et al. (2007). Novel action of apolipoprotein E (ApoE): ApoE isoform specif-
ically inhibits lipid-particle-mediated cholesterol release from neurons. Mol.
Neurodegener. 2, 9. doi: 10.1186/1750-1326-2-9
Goodman, L. (1953). Alzheimer’s disease; a clinico-pathologic analysis of twenty-
three cases with a theory on pathogenesis. J. Nerv. Ment. Dis. 118, 97–130. doi:
10.1097/00005053-195308000-00001
Greenough,M.A.,Volitakis, I., Li,Q. X., Laughton, K., Evin,G.,Ho,M., et al. (2011).
Presenilins promote the cellular uptake of copper and zinc and maintain copper
chaperone of SOD1-dependent copper/zinc superoxide dismutase activity. J. Biol.
Chem. 286, 9776–9786. doi: 10.1074/jbc.M110.163964
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A.,
Ostaszewski, B. L., et al. (1992). Amyloid beta-peptide is produced by cultured
cells during normal metabolism. Nature 359, 322–325. doi: 10.1038/359322a0
Haass, C., and Selkoe, D. J. (2007). Soluble protein oligomers in neurodegeneration:
lessons from the Alzheimer’s amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 8,
101–112. doi: 10.1038/nrm2101
Haber, F., and Weiss, J. (1934). The catalytic decomposition of hydrogen perox-
ide by iron salts. Proc. R. Soc. Lond. A. Math. Phys. Sci. 147, 332–351. doi:
10.1098/rspa.1934.0221
Haeffner, F., Smith, D. G., Barnham, K. J., and Bush, A. I. (2005). Model studies of
cholesterol and ascorbate oxidationby copper complexes: relevance toAlzheimer’s
disease beta-amyloid metallochemistry. J. Inorg. Biochem. 99, 2403–2422. doi:
10.1016/j.jinorgbio.2005.09.011
Hama, E., Shirotani, K., Iwata, N., and Saido, T. C. (2004). Effects of neprilysin
chimeric proteins targeted to subcellular compartments on amyloid beta pep-
tide clearance in primary neurons. J. Biol. Chem. 279, 30259–30264. doi:
10.1074/jbc.M401891200
Hayashi, H., Igbavboa, U., Hamanaka, H., Kobayashi, M., Fujita, S. C., Wood,
W. G., et al. (2002). Cholesterol is increased in the exofacial leaﬂet of synaptic
plasma membranes of human apolipoprotein E4 knock-in mice. Neuroreport 13,
383–386. doi: 10.1097/00001756-200203250-00004
Hesse, L., Beher, D., Masters, C. L., and Multhaup, G. (1994). The beta A4 amyloid
precursor protein binding to copper. FEBS Lett. 349, 109–116. doi: 10.1016/0014-
5793(94)00658-X
Frontiers in Aging Neuroscience www.frontiersin.org May 2014 | Volume 6 | Article 91 | 12
Wong et al. Metals and cholesterol in AD
Himes, R. A., Park, G. Y., Siluvai, G. S., Blackburn, N. J., and Karlin, K. D. (2008).
Structural studies of copper(I) complexes of amyloid-beta peptide fragments:
formation of two-coordinate bis(histidine) complexes. Angew. Chem. Int. Ed.
Engl. 47, 9084–9087. doi: 10.1002/anie.200803908
Hirsch-Reinshagen, V., Maia, L. F., Burgess, B. L., Blain, J. F., Naus, K. E., Mcisaac,
S. A., et al. (2005). The absence of ABCA1 decreases soluble ApoE levels but does
not diminish amyloid deposition in two murine models of Alzheimer disease.
J. Biol. Chem. 280, 43243–43256. doi: 10.1074/jbc.M508781200
Hoke, D. E., Tan, J. L., Ilaya, N. T., Culvenor, J. G., Smith, S. J., White, A. R., et al.
(2005). In vitro gamma-secretase cleavage of the Alzheimer’s amyloid precursor
protein correlates to a subset of presenilin complexes and is inhibited by zinc.
FEBS J. 272, 5544–5557. doi: 10.1111/j.1742-4658.2005.04950.x
Holmes, C. (2002). Genotype and phenotype inAlzheimer’s disease. Br. J. Psychiatry
180, 131–134. doi: 10.1192/bjp.180.2.131
Holtzman, D. M., Fagan, A. M., Mackey, B., Tenkova, T., Sartorius, L., Paul, S. M.,
et al. (2000). Apolipoprotein E facilitates neuritic and cerebrovascular plaque
formation in an Alzheimer’s disease model. Ann. Neurol. 47, 739–747. doi:
10.1002/1531-8249(200006)47:6<739::AID-ANA6>3.0.CO;2-8
Huang, L., Kirschke, C. P., and Gitschier, J. (2002). Functional characterization of a
novel mammalian zinc transporter, ZnT6. J. Biol. Chem. 277, 26389–26395. doi:
10.1074/jbc.M200462200
Huang, X., Atwood, C. S., Moir, R. D., Hartshorn, M. A., Tanzi, R. E., and Bush,
A. I. (2004). Trace metal contamination initiates the apparent auto-aggregation,
amyloidosis, and oligomerization of Alzheimer’s Abeta peptides. J. Biol. Inorg.
Chem. 9, 954–960. doi: 10.1007/s00775-004-0602-8
Huang, X., Atwood, C. S., Moir, R. D., Hartshorn, M. A., Vonsattel, J. P.,
Tanzi, R. E., et al. (1997). Zinc-induced Alzheimer’s Abeta1-40 aggregation is
mediated by conformational factors. J. Biol. Chem. 272, 26464–26470. doi:
10.1074/jbc.272.42.26464
Huang, X., Cuajungco, M. P., Atwood, C. S., Hartshorn, M. A., Tyndall, J.
D., Hanson, G. R., et al. (1999). Cu(II) potentiation of Alzheimer abeta
neurotoxicity. Correlation with cell-free hydrogen peroxide production and
metal reduction. J. Biol. Chem. 274, 37111–37116. doi: 10.1074/jbc.274.52.
37111
Hung, Y. H., Bush, A. I., and La Fontaine, S. (2013). Links between
copper and cholesterol in Alzheimer’s disease. Front. Physiol. 4:111. doi:
10.3389/fphys.2013.00111
Hung, Y. H., Faux, N. G., Killilea, D. W., Yanjanin, N., Firnkes, S., Volitakis, I., et al.
(2014). Altered transition metal homeostasis in Niemann–Pick disease, type C1.
Metallomics 6, 542–553. doi: 10.1039/c3mt00308f
Hung, Y. H., Robb, E. L., Volitakis, I., Ho, M., Evin, G., Li, Q. X., et al. (2009).
Paradoxical condensation of copper with elevated beta-amyloid in lipid rafts
under cellular copper deﬁciency conditions: implications for Alzheimer disease.
J. Biol. Chem. 284, 21899–21907. doi: 10.1074/jbc.M109.019521
Hur, J. Y., Welander, H., Behbahani, H., Aoki, M., Franberg, J., Winblad, B., et al.
(2008). Active gamma-secretase is localized to detergent-resistant membranes in
human brain. FEBS J. 275, 1174–1187. doi: 10.1111/j.1742-4658.2008.06278.x
Hureau, C., and Faller, P. (2009). Abeta-mediated ROS production by Cu ions:
structural insights, mechanisms and relevance to Alzheimer’s disease. Biochimie
91, 1212–1217. doi: 10.1016/j.biochi.2009.03.013
Irizarry,M. C., Cheung, B. S., Rebeck, G.W., Paul, S. M., Bales, K. R., and Hyman, B.
T. (2000). ApolipoproteinE affects the amount, form, and anatomical distribution
of amyloid beta-peptide deposition in homozygousAPP(V717F) transgenicmice.
Acta Neuropathol. 100, 451–458. doi: 10.1007/s004010000263
Irizarry, M. C., Deng, A., Lleo, A., Berezovska, O., Von Arnim, C. A., Martin-
Rehrmann, M., et al. (2004). Apolipoprotein E modulates gamma-secretase
cleavage of the amyloid precursor protein. J. Neurochem. 90, 1132–1143. doi:
10.1111/j.1471-4159.2004.02581.x
Iuliano, L. (2011). Pathways of cholesterol oxidation via non-enzymatic mecha-
nisms. Chem. Phys. Lipids 164, 457–468. doi: 10.1016/j.chemphyslip.2011.06.006
Iwatsubo, T. (2004). The gamma-secretase complex: machinery for intramembrane
proteolysis. Curr. Opin. Neurobiol 14, 379–383. doi: 10.1016/j.conb.2004.05.010
Janssen, J. C., Beck, J. A., Campbell, T. A., Dickinson, A., Fox, N. C., Harvey, R. J.,
et al. (2003). Early onset familial Alzheimer’s disease: mutation frequency in 31
families. Neurology 60, 235–239. doi: 10.1212/01.WNL.0000042088.22694.E3
Jiao, Y., and Yang, P. (2007). Mechanism of copper(II) inhibiting Alzheimer’s amy-
loid beta-peptide from aggregation: a molecular dynamics investigation. J. Phys.
Chem. B 111, 7646–7655. doi: 10.1021/jp0673359.
Jin, L. W., Shie, F. S., Maezawa, I., Vincent, I., and Bird, T. (2004). Intra-
cellular accumulation of amyloidogenic fragments of amyloid-beta precursor
protein in neurons with Niemann–Pick type C defects is associated with endo-
somal abnormalities. Am. J. Pathol. 164, 975–985. doi: 10.1016/S0002-9440(10)
63185-9
Kaden, D., Munter, L. M., Joshi, M., Treiber, C., Weise, C., Bethge, T., et al. (2008).
Homophilic interactions of the amyloid precursor protein (APP) ectodomain are
regulated by the loop region and affect beta-secretase cleavage of APP. J. Biol.
Chem. 283, 7271–7279. doi: 10.1074/jbc.M708046200
Kakio, A., Nishimoto, S., Yanagisawa, K., Kozutsumi, Y., and Matsuzaki, K. (2002).
Interactions of amyloid beta-protein with various gangliosides in raft-like mem-
branes: importance of GM1 ganglioside-bound form as an endogenous seed for
Alzheimer amyloid. Biochemistry 41, 7385–7390. doi: 10.1021/bi0255874
Kalvodova, L., Kahya, N., Schwille, P., Ehehalt, R., Verkade, P., Drechsel, D., et al.
(2005). Lipids as modulators of proteolytic activity of BACE: involvement of
cholesterol, glycosphingolipids, and anionic phospholipids in vitro. J. Biol. Chem.
280, 36815–36823. doi: 10.1074/jbc.M504484200
Karr, J. W., and Szalai, V. A. (2008). Cu(II) binding to monomeric, oligomeric, and
ﬁbrillar forms of the Alzheimer’s disease amyloid-beta peptide. Biochemistry 47,
5006–5016. doi: 10.1021/bi702423h
Kayed, R., Head, E., Thompson, J. L., Mcintire, T. M., Milton, S. C., Cotman,
C. W., et al. (2003). Common structure of soluble amyloid oligomers implies
commonmechanismof pathogenesis. Science 300, 486–489. doi: 10.1126/science.
1079469
Kelleher, S. L., and Lonnerdal, B. (2002). Zinc transporters in the rat mammary
gland respond to marginal zinc and vitamin A intakes during lactation. J. Nutr.
132, 3280–3285.
Kienlen-Campard, P., Tasiaux, B., Van Hees, J., Li, M., Huysseune, S., Sato, T.,
et al. (2008). Amyloidogenic processing but not amyloid precursor protein (APP)
intracellular C-terminal domain production requires a precisely oriented APP
dimer assembled by transmembrane GXXXG motifs. J. Biol. Chem. 283, 7733–
7744. doi: 10.1074/jbc.M707142200
Kim, J., Castellano, J. M., Jiang, H., Basak, J. M., Parsadanian, M., Pham, V., et al.
(2009). Overexpression of low-density lipoprotein receptor in the brainmarkedly
inhibits amyloid deposition and increases extracellular A beta clearance. Neuron
64, 632–644. doi: 10.1016/j.neuron.2009.11.013
Kim, S., Jeon, T. J., Oberai, A., Yang, D., Schmidt, J. J., and Bowie, J. U.
(2005). Transmembrane glycine zippers: physiological and pathological roles
in membrane proteins. Proc. Natl. Acad. Sci. U.S.A. 102, 14278–14283. doi:
10.1073/pnas.0501234102
Kim, S. I., Yi, J. S., and Ko, Y. G. (2006). Amyloid beta oligomerization is induced by
brain lipid rafts. J. Cell. Biochem. 99, 878–889. doi: 10.1002/jcb.20978
Kodam, A., Maulik, M., Peake, K., Amritraj, A., Vetrivel, K. S., Thinakaran, G.,
et al. (2010). Altered levels and distribution of amyloid precursor protein and its
processing enzymes in Niemann–Pick type C1-deﬁcient mouse brains. Glia 58,
1267–1281. doi: 10.1002/glia.21001
Kojro, E., Gimpl, G., Lammich, S., Marz, W., and Fahrenholz, F. (2001).
Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the
alpha-secretase ADAM 10. Proc. Natl. Acad. Sci. U.S.A. 98, 5815–5820. doi:
10.1073/pnas.081612998
Koldamova, R., Staufenbiel,M., and Lefterov, I. (2005). Lack of ABCA1 considerably
decreases brain ApoE level and increases amyloid deposition in APP23 mice.
J. Biol. Chem. 280, 43224–43235. doi: 10.1074/jbc.M504513200
Kosicek, M., Malnar, M., Goate, A., and Hecimovic, S. (2010). Cholesterol accu-
mulation in Niemann–Pick type C (NPC) model cells causes a shift in APP
localization to lipid rafts. Biochem. Biophys. Res. Commun. 393, 404–409. doi:
10.1016/j.bbrc.2010.02.007
Kosik, K. S., Joachim, C. L., and Selkoe, D. J. (1986). Microtubule-associated protein
tau (tau) is a major antigenic component of paired helical ﬁlaments in Alzheimer
disease. Proc. Natl. Acad. Sci. U.S.A. 83, 4044–4048. doi: 10.1073/pnas.83.11.4044
Kuhn, P. H., Wang, H., Dislich, B., Colombo, A., Zeitschel, U., Ellwart, J. W., et al.
(2010). ADAM10 is the physiologically relevant, constitutive alpha-secretase of
the amyloid precursor protein in primary neurons. EMBO J. 29, 3020–3032. doi:
10.1038/emboj.2010.167
Lammich, S., Kojro, E., Postina, R., Gilbert, S., Pfeiffer, R., Jasionowski, M., et al.
(1999). Constitutive and regulated alpha-secretase cleavage of Alzheimer’s amy-
loid precursor protein by a disintegrin metalloprotease. Proc. Natl. Acad. Sci.
U.S.A. 96, 3922–3927. doi: 10.1073/pnas.96.7.3922
Frontiers in Aging Neuroscience www.frontiersin.org May 2014 | Volume 6 | Article 91 | 13
Wong et al. Metals and cholesterol in AD
Ledesma, M. D., Abad-Rodriguez, J., Galvan, C., Biondi, E., Navarro, P.,
Delacourte, A., et al. (2003). Raft disorganization leads to reduced plas-
min activity in Alzheimer’s disease brains. EMBO Rep. 4, 1190–1196. doi:
10.1038/sj.embor.7400021
Lee, J. Y., Cole, T. B., Palmiter, R. D., Suh, S. W., and Koh, J. Y. (2002). Contribution
by synaptic zinc to the gender-disparate plaque formation in human Swedish
mutant APP transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 99, 7705–7710. doi:
10.1073/pnas.092034699
Lee, S. J., Liyanage, U., Bickel, P. E., Xia, W., Lansbury, P. T. Jr., and Kosik, K. S.
(1998). A detergent-insoluble membrane compartment contains A beta in vivo.
Nat. Med. 4, 730–734. doi: 10.1038/nm0698-730
Lee, V. M., Balin, B. J., Otvos, L. Jr., and Trojanowski, J. Q. (1991). A68: a major
subunit of paired helical ﬁlaments and derivatized forms of normal Tau. Science
251, 675–678. doi: 10.1126/science.1899488
Lei, P., Ayton, S., Finkelstein, D. I., Spoerri, L., Ciccotosto, G. D., Wright, D. K.,
et al. (2012). Tau deﬁciency induces parkinsonism with dementia by impairing
APP-mediated iron export. Nat. Med. 18, 291–295. doi: 10.1038/nm.2613
Lesne, S., Kotilinek, L., and Ashe, K. H. (2008). Plaque-bearing mice with reduced
levels of oligomeric amyloid-beta assemblies have intact memory function.
Neuroscience 151, 745–749. doi: 10.1016/j.neuroscience.2007.10.054
Lichtenthaler, S. F. (2011). alpha-secretase in Alzheimer’s disease: molecular iden-
tity, regulation and therapeutic potential. J. Neurochem. 116, 10–21. doi:
10.1111/j.1471-4159.2010.07081.x
Lin, M. S., Chen, L. Y., Wang, S. S., Chang, Y., and Chen, W. Y. (2008). Examining
the levels of ganglioside and cholesterol in cell membrane on attenuation the
cytotoxicity of beta-amyloid peptide. Colloids Surf. B Biointerfaces 65, 172–177.
doi: 10.1016/j.colsurfb.2008.03.012
Lind, S. E., Mcdonagh, J. R., and Smith, C. J. (1993). Oxidative inactivation of
plasmin and other serine proteases by copper and ascorbate. Blood 82, 1522–1531.
Ling, Y., Morgan, K., and Kalsheker, N. (2003). Amyloid precursor protein (APP)
and the biology of proteolytic processing: relevance to Alzheimer’s disease. Int. J.
Biochem. Cell Biol. 35, 1505–1535. doi: 10.1016/S1357-2725(03)00133-X
Linkous, D. H., Adlard, P. A., Wanschura, P. B., Conko, K. M., and Flinn, J. M.
(2009). The effects of enhanced zinc on spatial memory and plaque formation in
transgenic mice. J. Alzheimers. Dis. 18, 565–579. doi: 10.3233/JAD-2009-1162
Linkous, D. H., Flinn, J. M., Koh, J. Y., Lanzirotti, A., Bertsch, P. M., Jones, B.
F., et al. (2008). Evidence that the ZNT3 protein controls the total amount
of elemental zinc in synaptic vesicles. J. Histochem. Cytochem. 56, 3–6. doi:
10.1369/jhc.6A7035.2007
Liu, B., Moloney, A., Meehan, S., Morris, K., Thomas, S. E., Serpell, L.
C., et al. (2011). Iron promotes the toxicity of amyloid beta peptide by
impeding its ordered aggregation. J. Biol. Chem. 286, 4248–4256. doi:
10.1074/jbc.M110.158980
Lovell, M. A., Robertson, J. D., Teesdale, W. J., Campbell, J. L., and Markesbery, W.
R. (1998). Copper, iron and zinc in Alzheimer’s disease senile plaques. J. Neurol.
Sci. 158, 47–52. doi: 10.1016/S0022-510X(98)00092-6
Lovell, M. A., Smith, J. L., Xiong, S., and Markesbery, W. R. (2005). Alterations in
zinc transporter protein-1 (ZnT-1) in the brain of subjects with mild cognitive
impairment, early, and late-stage Alzheimer’s disease. Neurotox. Res. 7, 265–271.
doi: 10.1007/BF03033884
Lund, E.G.,Guileyardo, J.M., andRussell,D.W. (1999). cDNAcloningof cholesterol
24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc. Natl.
Acad. Sci. U.S.A. 96, 7238–7243. doi: 10.1073/pnas.96.13.7238
Lutjohann, D., and von Bergmann, K. (2003). 24S-hydroxycholesterol: a marker of
brain cholesterol metabolism. Pharmacopsychiatry 36(Suppl. 2), S102–S106. doi:
10.1055/s-2003-43053
Mainous, A. G. III, Eschenbach, S. L., Wells, B. J., Everett, C. J., and Gill, J. M.
(2005). Cholesterol, transferrin saturation, and the development of dementia
and Alzheimer’s disease: results from an 18-year population-based cohort. Fam.
Med. 37, 36–42.
Malnar, M., Kosicek, M., Lisica, A., Posavec, M., Krolo, A., Njavro, J., et al. (2012).
Cholesterol-depletion correctsAPPandBACE1misstrafﬁcking inNPC1-deﬁcient
cells. Biochim. Biophys. Acta 1822, 1270–1283. doi: 10.1016/j.bbadis.2012.04.002
Malnar, M., Kosicek, M., Mitterreiter, S., Omerbasic, D., Lichtenthaler, S. F.,
Goate, A., et al. (2010). Niemann–Pick type C cells show cholesterol depen-
dent decrease of APP expression at the cell surface and its increased processing
through the beta-secretase pathway. Biochim. Biophys. Acta 1802, 682–691. doi:
10.1016/j.bbadis.2010.05.006
Mantyh, P. W., Ghilardi, J. R., Rogers, S., Demaster, E., Allen, C.
J., Stimson, E. R., et al. (1993). Aluminum, iron, and zinc ions pro-
mote aggregation of physiological concentrations of beta-amyloid pep-
tide. J. Neurochem. 61, 1171–1174. doi: 10.1111/j.1471-4159.1993.tb0
3639.x
Marquer, C., Devauges, V., Cossec, J. C., Liot, G., Lecart, S., Saudou, F., et al. (2011).
Local cholesterol increase triggers amyloid precursor protein-Bace1 clustering in
lipid rafts and rapid endocytosis. FASEB J. 25, 1295–1305. doi: 10.1096/fj.10-
168633
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., Mcdonald, B. L.,
and Beyreuther, K. (1985). Amyloid plaque core protein in Alzheimer dis-
ease and Down syndrome. Proc. Natl. Acad. Sci. U.S.A. 82, 4245–4249. doi:
10.1073/pnas.82.12.4245
Matsuzaki, K., Kato, K., and Yanagisawa, K. (2010). Abeta polymerization through
interaction with membrane gangliosides. Biochim. Biophys. Acta 1801, 868–877.
doi: 10.1016/j.bbalip.2010.01.008
Maulik, M., Westaway, D., Jhamandas, J. H., and Kar, S. (2013). Role of cholesterol
in APP metabolism and its signiﬁcance in Alzheimer’s disease pathogenesis. Mol.
Neurobiol. 47, 37–63. doi: 10.1007/s12035-012-8337-y
Maynard, C. J., Cappai, R., Volitakis, I., Cherny, R. A., White, A. R., Beyreuther, K.,
et al. (2002). Overexpressionof Alzheimer’s disease amyloid-beta opposes the age-
dependent elevations of brain copper and iron. J. Biol. Chem. 277, 44670–44676.
doi: 10.1074/jbc.M204379200
Michikawa, M., Fan, Q. W., Isobe, I., and Yanagisawa, K. (2000). Apolipoprotein
E exhibits isoform-speciﬁc promotion of lipid efﬂux from astrocytes and neu-
rons in culture. J. Neurochem. 74, 1008–1016. doi: 10.1046/j.1471-4159.2000.
0741008.x
Miller, L. M., Wang, Q., Telivala, T. P., Smith, R. J., Lanzirotti, A., and
Miklossy, J. (2006). Synchrotron-based infrared and X-ray imaging shows
focalized accumulation of Cu and Zn co-localized with beta-amyloid deposits
in Alzheimer’s disease. J. Struct. Biol. 155, 30–37. doi: 10.1016/j.jsb.2005.
09.004
Miyashita, N., Straub, J. E., Thirumalai, D., and Sugita, Y. (2009). Transmembrane
structures of amyloid precursor protein dimer predicted by replica-exchange
molecular dynamics simulations. J. Am. Chem. Soc. 131, 3438–3439. doi:
10.1021/ja809227c
Miyata, M., and Smith, J. D. (1996). Apolipoprotein E allele-speciﬁc antioxidant
activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides.
Nat. Genet. 14, 55–61. doi: 10.1038/ng0996-55
Moir, R. D., Atwood, C. S., Romano, D. M., Laurans, M. H., Huang, X., Bush,
A. I., et al. (1999). Differential effects of apolipoprotein E isoforms on metal-
induced aggregation of A beta using physiological concentrations. Biochemistry
38, 4595–4603. doi: 10.1021/bi982437d
Morris, M. C., Evans, D. A., Bienias, J. L., Tangney, C. C., Bennett, D. A., Aggarwal,
N., et al. (2003). Dietary fats and the risk of incident Alzheimer disease. Arch.
Neurol. 60, 194–200. doi: 10.1001/archneur.60.2.194
Morris, M. C., Evans, D. A., Bienias, J. L., Tangney, C. C., and Wil-
son, R. S. (2004). Dietary fat intake and 6-year cognitive change in
an older biracial community population. Neurology 62, 1573–1579. doi:
10.1212/01.WNL.0000123250.82849.B6
Morris, M. C., Evans, D. A., Tangney, C. C., Bienias, J. L., Schneider, J. A.,
Wilson, R. S., et al. (2006). Dietary copper and high saturated and trans fat
intakes associated with cognitive decline. Arch. Neurol. 63, 1085–1088. doi:
10.1001/archneur.63.8.1085
Muller-Spahn, F., and Hock, C. (1999). Risk factors and differential diagnosis of
Alzheimer’s disease. Eur. Arch. Psychiatry Clin. Neurosci. 249(Suppl. 3), 37–42.
doi: 10.1007/PL00014172
Multhaup, G., Schlicksupp, A., Hesse, L., Beher, D., Ruppert, T., Masters,
C. L., et al. (1996). The amyloid precursor protein of Alzheimer’s disease
in the reduction of copper(II) to copper(I). Science 271, 1406–1409. doi:
10.1126/science.271.5254.1406
Munter, L. M., Voigt, P., Harmeier, A., Kaden, D., Gottschalk, K. E., Weise, C.,
et al. (2007). GxxxGmotifs within the amyloid precursor protein transmembrane
sequence are critical for the etiology of Abeta42. EMBO J. 26, 1702–1712. doi:
10.1038/sj.emboj.7601616
Murray, I. V., Sindoni,M. E., and Axelsen, P. H. (2005). Promotion of oxidative lipid
membrane damage by amyloid beta proteins. Biochemistry 44, 12606–12613. doi:
10.1021/bi050926p
Frontiers in Aging Neuroscience www.frontiersin.org May 2014 | Volume 6 | Article 91 | 14
Wong et al. Metals and cholesterol in AD
Needham, B. E., Ciccotosto, G. D., and Cappai, R. (2014). Combined deletions
of amyloid precursor protein and amyloid precursor-like protein 2 reveal dif-
ferent effects on mouse brain metal homeostasis. Metallomics 6, 598–603. doi:
10.1039/c3mt00358b
Nelson, T. J., and Alkon, D. L. (2005). Oxidation of cholesterol by amyloid pre-
cursor protein and beta-amyloid peptide. J. Biol. Chem. 280, 7377–7387. doi:
10.1074/jbc.M409071200
Noda, Y., Asada, M., Kubota, M., Maesako, M., Watanabe, K., Uemura, M., et al.
(2013). Copper enhances APP dimerization and promotes Abeta production.
Neurosci. Lett. 547, 10–15. doi: 10.1016/j.neulet.2013.04.057
Okada, T., Ikeda, K., Wakabayashi, M., Ogawa, M., and Matsuzaki, K. (2008). For-
mation of toxic Abeta(1-40) ﬁbrils on GM1 ganglioside-containing membranes
mimicking lipid rafts: polymorphisms in Abeta(1-40) ﬁbrils. J. Mol. Biol. 382,
1066–1074. doi: 10.1016/j.jmb.2008.07.072
Opazo, C., Huang, X., Cherny, R. A., Moir, R. D., Roher, A. E., White, A. R.,
et al. (2002). Metalloenzyme-like activity of Alzheimer’s disease beta-amyloid.
Cu-dependent catalytic conversion of dopamine, cholesterol, and biological
reducing agents to neurotoxic H(2)O(2). J. Biol. Chem. 277, 40302–40308. doi:
10.1074/jbc.M206428200
Osenkowski, P., Ye, W., Wang, R., Wolfe, M. S., and Selkoe, D. J. (2008). Direct
and potent regulation of gamma-secretase by its lipid microenvironment. J. Biol.
Chem. 283, 22529–22540. doi: 10.1074/jbc.M801925200
Panchal, M., Loeper, J., Cossec, J. C., Perruchini, C., Lazar, A., Pompon, D.,
et al. (2010). Enrichment of cholesterol in microdissected Alzheimer’s disease
senile plaques as assessed by mass spectrometry. J. Lipid Res. 51, 598–605. doi:
10.1194/jlr.M001859
Park, I. H., Jung, M. W., Mori, H., and Mook-Jung, I. (2001). Zinc enhances
synthesis of presenilin 1 in mouse primary cortical culture. Biochem. Biophys.
Res. Commun. 285, 680–688. doi: 10.1006/bbrc.2001.5243
Parkin, E. T., Turner, A. J., and Hooper, N. M. (1999). Amyloid precur-
sor protein, although partially detergent-insoluble in mouse cerebral cortex,
behaves as an atypical lipid raft protein. Biochem. J. 344(Pt 1), 23–30. doi:
10.1042/0264-6021:3440023
Perrone, L., Mothes, E., Vignes, M., Mockel, A., Figueroa, C., Miquel, M. C.,
et al. (2010). Copper transfer from Cu-Abeta to human serum albumin inhibits
aggregation, radical production and reduces Abeta toxicity. Chembiochem 11,
110–118. doi: 10.1002/cbic.200900474
Phinney, A. L., Drisaldi, B., Schmidt, S. D., Lugowski, S., Coronado, V., Liang,
Y., et al. (2003). In vivo reduction of amyloid-beta by a mutant copper trans-
porter. Proc. Natl. Acad. Sci. U.S.A. 100, 14193–14198. doi: 10.1073/pnas.23328
51100
Pierrot, N., Tyteca, D., D’Auria, L., Dewachter, I., Gailly, P., Hendrickx, A.,
et al. (2013). Amyloid precursor protein controls cholesterol turnover needed
for neuronal activity. EMBO Mol. Med. 5, 608–625. doi: 10.1002/emmm.
201202215
Poirier, J. (2003). Apolipoprotein E and cholesterol metabolism in the pathogen-
esis and treatment of Alzheimer’s disease. Trends Mol. Med. 9, 94–101. doi:
10.1016/S1471-4914(03)00007-8
Poirier, J., Baccichet, A., Dea, D., and Gauthier, S. (1993). Cholesterol synthesis and
lipoprotein reuptake during synaptic remodelling in hippocampus in adult rats.
Neuroscience 55, 81–90. doi: 10.1016/0306-4522(93)90456-P
Puglielli, L., Friedlich, A. L., Setchell, K. D., Nagano, S., Opazo, C., Cherny, R. A.,
et al. (2005). Alzheimer disease beta-amyloid activity mimics cholesterol oxidase.
J. Clin. Invest. 115, 2556–2563. doi: 10.1172/JCI23610
Ramstedt, B., and Slotte, J. P. (2006). Sphingolipids and the formation of sterol-
enriched ordered membrane domains. Biochim. Biophys. Acta 1758, 1945–1956.
doi: 10.1016/j.bbamem.2006.05.020
Raux, G., Guyant-Marechal, L., Martin, C., Bou, J., Penet, C., Brice, A., et al. (2005).
Molecular diagnosis of autosomal dominant early onset Alzheimer’s disease: an
update. J. Med. Genet. 42, 793–795. doi: 10.1136/jmg.2005.033456
Reiman, E. M., Chen, K., Liu, X., Bandy, D., Yu, M., Lee, W., et al. (2009). Fib-
rillar amyloid-beta burden in cognitively normal people at 3 levels of genetic
risk for Alzheimer’s disease. Proc. Natl. Acad. Sci. U.S.A. 106, 6820–6825. doi:
10.1073/pnas.0900345106
Riddell, D. R., Zhou, H., Comery, T. A., Kouranova, E., Lo, C. F., Warwick, H. K.,
et al. (2007). The LXR agonist TO901317 selectively lowers hippocampal Abeta42
and improves memory in the Tg2576 mouse model of Alzheimer’s disease. Mol.
Cell. Neurosci. 34, 621–628. doi: 10.1016/j.mcn.2007.01.011
Rogers, J. T., Randall, J. D., Cahill, C. M., Eder, P. S., Huang, X., Gunshin, H.,
et al. (2002). An iron-responsive element type II in the 5′-untranslated region of
the Alzheimer’s amyloid precursor protein transcript. J. Biol. Chem. 277, 45518–
45528. doi: 10.1074/jbc.M207435200
Roychaudhuri, R., Yang, M., Hoshi, M. M., and Teplow, D. B. (2009). Amyloid
beta-protein assembly and Alzheimer disease. J. Biol. Chem. 284, 4749–4753. doi:
10.1074/jbc.R800036200
Rozga,M., Protas,A.M., Jablonowska,A.,Dadlez,M., andBal,W. (2009). TheCu(II)
complex of Abeta40 peptide in ammoniumacetate solutions. Evidence for ternary
species formation. Chem. Commun. (Camb.) 1374–1376. doi: 10.1039/b819616h
Runz, H., Rietdorf, J., Tomic, I., De Bernard,M., Beyreuther, K., Pepperkok, R., et al.
(2002). Inhibition of intracellular cholesterol transport alters presenilin localiza-
tion and amyloid precursor protein processing in neuronal cells. J. Neurosci. 22,
1679–1689.
Sato, K., Tanabe, C., Yonemura, Y.,Watahiki, H., Zhao, Y., Yagishita, S., et al. (2012).
Localization of mature neprilysin in lipid rafts. J. Neurosci. Res. 90, 870–877. doi:
10.1002/jnr.22796
Sato, T., Tang, T. C., Reubins, G., Fei, J. Z., Fujimoto, T., Kienlen-Campard,
P., et al. (2009). A helix-to-coil transition at the epsilon-cut site in the
transmembrane dimer of the amyloid precursor protein is required for prote-
olysis. Proc. Natl. Acad. Sci. U.S.A. 106, 1421–1426. doi: 10.1073/pnas.08122
61106
Scheuermann, S., Hambsch, B., Hesse, L., Stumm, J., Schmidt, C., Beher, D., et al.
(2001). Homodimerization of amyloid precursor protein and its implication in
the amyloidogenic pathway of Alzheimer’s disease. J. Biol. Chem. 276, 33923–
33929. doi: 10.1074/jbc.M105410200
Schneider, A., Rajendran, L., Honsho, M., Gralle, M., Donnert, G., Wouters, F.,
et al. (2008). Flotillin-dependent clustering of the amyloid precursor protein
regulates its endocytosis and amyloidogenic processing in neurons. J. Neurosci.
28, 2874–2882. doi: 10.1523/JNEUROSCI.5345-07.2008
Schneider, A., Schulz-Schaeffer, W., Hartmann, T., Schulz, J. B., and Simons, M.
(2006). Cholesterol depletion reduces aggregation of amyloid-beta peptide in
hippocampal neurons. Neurobiol. Dis. 23, 573–577. doi: 10.1016/j.nbd.2006.
04.015
Schubert, D., and Chevion, M. (1995). The role of iron in beta amyloid toxicity.
Biochem. Biophys. Res. Commun. 216, 702–707. doi: 10.1006/bbrc.1995.2678
Shankar, G. M., andWalsh, D. M. (2009). Alzheimer’s disease: synaptic dysfunction
and Abeta. Mol. Neurodegener. 4, 48. doi: 10.1186/1750-1326-4-48
Shearer, J., and Szalai, V. A. (2008). The amyloid-beta peptide of Alzheimer’s disease
binds Cu(I) in a linear bis-his coordination environment: insight into a possible
neuroprotective mechanism for the amyloid-beta peptide. J. Am. Chem. Soc. 130,
17826–17835. doi: 10.1021/ja805940m
Shinall, H., Song, E. S., and Hersh, L. B. (2005). Susceptibility of amyloid beta
peptide degrading enzymes to oxidative damage: a potential Alzheimer’s disease
spiral. Biochemistry 44, 15345–15350. doi: 10.1021/bi050650l
Shoji, M. (2002). Cerebrospinal ﬂuid Abeta40 and Abeta42: natural course and
clinical usefulness. Front. Biosci. 7:d997–d1006. doi: 10.2741/shoji
Simons, A., Ruppert, T., Schmidt, C., Schlicksupp, A., Pipkorn, R., Reed, J., et al.
(2002). Evidence for a copper-binding superfamily of the amyloid precursor
protein. Biochemistry 41, 9310–9320. doi: 10.1021/bi0258647
Simons, M., Keller, P., De Strooper, B., Beyreuther, K., Dotti, C. G., and
Simons, K. (1998). Cholesterol depletion inhibits the generation of beta-amyloid
in hippocampal neurons. Proc. Natl. Acad. Sci. U.S.A. 95, 6460–6464. doi:
10.1073/pnas.95.11.6460
Simons, M., Keller, P., Dichgans, J., and Schulz, J. B. (2001). Cholesterol
and Alzheimer’s disease: is there a link? Neurology 57, 1089–1093. doi:
10.1212/WNL.57.6.1089
Sinha, S., Anderson, J. P., Barbour, R., Basi, G. S., Caccavello, R., Davis, D., et al.
(1999). Puriﬁcation and cloning of amyloid precursor protein beta-secretase from
human brain. Nature 402, 537–540. doi: 10.1038/990114
Smith, D. G., Ciccotosto, G. D., Tew, D. J., Perez, K., Curtain, C. C., Boas, J. F.,
et al. (2010). Histidine 14 modulates membrane binding and neurotoxicity of the
Alzheimer’s disease amyloid-beta peptide. J. Alzheimers Dis. 19, 1387–1400. doi:
10.3233/JAD-2010-1334
Smith, D. P., Smith, D. G., Curtain, C. C., Boas, J. F., Pilbrow, J. R., Ciccoto-
sto, G. D., et al. (2006). Copper-mediated amyloid-beta toxicity is associated
with an intermolecular histidine bridge. J. Biol. Chem. 281, 15145–15154. doi:
10.1074/jbc.M600417200
Frontiers in Aging Neuroscience www.frontiersin.org May 2014 | Volume 6 | Article 91 | 15
Wong et al. Metals and cholesterol in AD
Smith, M. A., Perry, G., Richey, P. L., Sayre, L. M., Anderson, V. E., Beal, M.
F., et al. (1996). Oxidative damage in Alzheimer’s. Nature 382, 120–121. doi:
10.1038/382120b0
Smith, M. A., Richey Harris, P. L., Sayre, L. M., Beckman, J. S., and Perry, G. (1997).
Widespread peroxynitrite-mediated damage in Alzheimer’s disease. J. Neurosci.
17, 2653–2657.
Song, Y., Hustedt, E. J., Brandon, S., and Sanders, C. R. (2013). Competition
between homodimerization and cholesterol binding to the C99 domain of the
amyloid precursor protein. Biochemistry 52, 5051–5064. doi: 10.1021/bi400735x
Sparks, D. L., Petanceska, S., Sabbagh, M., Connor, D., Soares, H., Adler, C.,
et al. (2005). Cholesterol, copper and Abeta in controls, MCI, AD and the AD
cholesterol-lowering treatment trial (ADCLT). Curr. Alzheimer Res. 2, 527–539.
doi: 10.2174/156720505774932296
Sparks, D. L., Scheff, S. W., Hunsaker, J. C. III, Liu, H., Landers, T., and Gross,
D. R. (1994). Induction of Alzheimer-like beta-amyloid immunoreactivity in
the brains of rabbits with dietary cholesterol. Exp. Neurol. 126, 88–94. doi:
10.1006/exnr.1994.1044
Sparks, D. L., and Schreurs, B. G. (2003). Trace amounts of copper in
water induce beta-amyloid plaques and learning deﬁcits in a rabbit model
of Alzheimer’s disease. Proc. Natl. Acad. Sci. U.S.A. 100, 11065–11069. doi:
10.1073/pnas.1832769100
Spoerri, L., Vella, L. J., Pham, C. L., Barnham, K. J., and Cappai, R. (2012). The
amyloid precursor protein copper binding domain histidine residues 149 and 151
mediate APP stability and metabolism. J. Biol. Chem. 287, 26840–26853. doi:
10.1074/jbc.M112.355743
Sponne, I., Fifre,A.,Koziel,V.,Oster, T.,Olivier, J. L., andPillot, T. (2004).Membrane
cholesterol interferes with neuronal apoptosis induced by soluble oligomers but
not ﬁbrils of amyloid-beta peptide. FASEB J. 18, 836–838. doi: 10.1096/fj.03-
0372fje
Stefani, M., and Liguri, G. (2009). Cholesterol in Alzheimer’s disease: unresolved
questions. Curr. Alzheimer Res. 6, 15–29. doi: 10.2174/156720509787313899
Stoltenberg, M., Bruhn, M., Sondergaard, C., Doering, P., West, M. J., Larsen, A.,
et al. (2005). Immersion autometallographic tracing of zinc ions in Alzheimer
beta-amyloid plaques. Histochem. Cell Biol. 123, 605–611. doi: 10.1007/s00418-
005-0787-0
Stoltenberg, M., Bush, A. I., Bach, G., Smidt, K., Larsen, A., Rungby, J., et al. (2007).
Amyloid plaques arise from zinc-enriched cortical layers in APP/PS1 transgenic
mice and are paradoxically enlarged with dietary zinc deﬁciency. Neuroscience
150, 357–369. doi: 10.1016/j.neuroscience.2007.09.025
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild,
J., Salvesen, G. S., et al. (1993). Apolipoprotein E: high-avidity binding to beta-
amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer
disease. Proc. Natl. Acad. Sci. U.S.A. 90, 1977–1981. doi: 10.1073/pnas.90.
5.1977
Suh, S. W., Jensen, K. B., Jensen, M. S., Silva, D. S., Kesslak, P. J., Danscher, G.,
et al. (2000). Histochemically-reactive zinc in amyloid plaques, angiopathy, and
degenerating neurons of Alzheimer’s diseased brains. Brain Res. 852, 274–278.
doi: 10.1016/S0006-8993(99)02096-X
Swaiman, K. F., and Machen, V. L. (1984). Iron uptake by mammalian cortical
neurons. Ann. Neurol. 16, 66–70. doi: 10.1002/ana.410160113
Syme, C. D., Nadal, R. C., Rigby, S. E., and Viles, J. H. (2004). Copper binding to
the amyloid-beta (Abeta) peptide associated with Alzheimer’s disease: folding,
coordination geometry, pH dependence, stoichiometry, and afﬁnity of Abeta-(1-
28): insights from a range of complementary spectroscopic techniques. J. Biol.
Chem. 279, 18169–18177. doi: 10.1074/jbc.M313572200
Syme, C. D., and Viles, J. H. (2006). Solution 1H NMR investigation of Zn2+ and
Cd2+ binding to amyloid-beta peptide (Abeta) of Alzheimer’s disease. Biochim.
Biophys. Acta 1764, 246–256. doi: 10.1016/j.bbapap.2005.09.012
Tabner, B. J., Turnbull, S., El-Agnaf, O. M., and Allsop, D. (2002). Formation of
hydrogen peroxide and hydroxyl radicals from A(beta) and alpha-synuclein as a
possible mechanism of cell death in Alzheimer’s disease and Parkinson’s disease.
Free Radic. Biol. Med. 32, 1076–1083. doi: 10.1016/S0891-5849(02)00801-8
Tanzi, R. E., and Bertram, L. (2005). Twenty years of the Alzheimer’s dis-
ease amyloid hypothesis: a genetic perspective. Cell 120, 545–555. doi:
10.1016/j.cell.2005.02.008
Tougu,V., Karaﬁn, A., and Palumaa, P. (2008). Binding of zinc(II) and copper(II) to
the full-length Alzheimer’s amyloid-beta peptide. J. Neurochem. 104, 1249–1259.
doi: 10.1111/j.1471-4159.2007.05061.x
Tougu, V., Karaﬁn, A., Zovo, K., Chung, R. S., Howells, C., West, A. K., et al.
(2009). Zn(II)- and Cu(II)-induced non-ﬁbrillar aggregates of amyloid-beta (1-
42) peptide are transformed to amyloid ﬁbrils, both spontaneously and under the
inﬂuence of metal chelators. J. Neurochem. 110, 1784–1795. doi: 10.1111/j.1471-
4159.2009.06269.x
Valensin, D., Mancini, F. M., Luczkowski, M., Janicka, A., Wisniewska, K., Gaggelli,
E., et al. (2004). Identiﬁcation of a novel high afﬁnity copper binding site in the
APP(145–155) fragment of amyloid precursor protein. Dalton Trans. 16–22. doi:
10.1039/b312411h
Vance, J. E. (2006). Lipid imbalance in the neurological disorder, Niemann–Pick C
disease. FEBS Lett. 580, 5518–5524. doi: 10.1016/j.febslet.2006.06.008
Vanier, M. T., and Millat, G. (2003). Niemann–Pick disease type C. Clin. Genet. 64,
269–281. doi: 10.1034/j.1399-0004.2003.00147.x
Vanmierlo, T., Rutten, K., Dederen, J., Bloks, V. W., Van Vark-Van Der Zee, L.
C., Kuipers, F., et al. (2011). Liver X receptor activation restores memory in
aged AD mice without reducing amyloid. Neurobiol. Aging 32, 1262–1272. doi:
10.1016/j.neurobiolaging.2009.07.005
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis,
P., et al. (1999). Beta-secretase cleavage of Alzheimer’s amyloid precursor pro-
tein by the transmembrane aspartic protease BACE. Science 286, 735–741. doi:
10.1126/science.286.5440.735
Vekrellis, K., Ye, Z., Qiu, W. Q., Walsh, D., Hartley, D., Chesneau, V., et al. (2000).
Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by
insulin-degrading enzyme. J. Neurosci. 20, 1657–1665.
Venti, A., Giordano, T., Eder, P., Bush, A. I., Lahiri, D. K., Greig, N. H., et al.
(2004). The integrated role of desferrioxamine and phenserine targeted to an
iron-responsive element in the APP-mRNA 5′-untranslated region. Ann. N. Y.
Acad. Sci. 1035, 34–48. doi: 10.1196/annals.1332.003
Vetrivel, K. S., Cheng, H., Lin, W., Sakurai, T., Li, T., Nukina, N., et al. (2004).
Association of gamma-secretase with lipid rafts in post-Golgi and endosome
membranes. J. Biol. Chem. 279, 44945–44954. doi: 10.1074/jbc.M407986200
Vigo-Pelfrey, C., Lee, D., Keim, P., Lieberburg, I., and Schenk, D. B. (1993). Charac-
terization of beta-amyloid peptide fromhuman cerebrospinal ﬂuid. J. Neurochem.
61, 1965–1968. doi: 10.1111/j.1471-4159.1993.tb09841.x
Wahrle, S., Das, P., Nyborg, A. C., Mclendon, C., Shoji, M., Kawarabayashi,
T., et al. (2002). Cholesterol-dependent gamma-secretase activity in buoy-
ant cholesterol-rich membrane microdomains. Neurobiol. Dis. 9, 11–23. doi:
10.1006/nbdi.2001.0470
Wahrle, S. E., Jiang, H., Parsadanian, M., Hartman, R. E., Bales, K. R., Paul, S.
M., et al. (2005). Deletion of Abca1 increases Abeta deposition in the PDAPP
transgenic mouse model of Alzheimer disease. J. Biol. Chem. 280, 43236–43242.
doi: 10.1074/jbc.M508780200
Wahrle, S. E., Jiang, H., Parsadanian, M., Kim, J., Li, A., Knoten, A., et al.
(2008). Overexpression of ABCA1 reduces amyloid deposition in the PDAPP
mouse model of Alzheimer disease. J. Clin. Invest. 118, 671–682. doi: 10.1172/
JCI33622
Wahrle, S. E., Jiang, H., Parsadanian, M., Legleiter, J., Han, X., Fryer, J. D., et al.
(2004). ABCA1 is required for normal central nervous system ApoE levels and
for lipidation of astrocyte-secreted apoE. J. Biol. Chem. 279, 40987–40993. doi:
10.1074/jbc.M407963200
Waldron, K. J., Rutherford, J. C., Ford, D., and Robinson, N. J. (2009). Metallopro-
teins and metal sensing. Nature 460, 823–830. doi: 10.1038/nature08300
Walkley, S. U., and Suzuki, K. (2004). Consequences of NPC1 and NPC2 loss
of function in mammalian neurons. Biochim. Biophys. Acta 1685, 48–62. doi:
10.1016/j.bbalip.2004.08.011
Walter, J., Schindzielorz, A., Hartung, B., and Haass, C. (2000). Phosphorylation of
the beta-amyloid precursor protein at the cell surface by ectocasein kinases 1 and
2. J. Biol. Chem. 275, 23523–23529. doi: 10.1074/jbc.M002850200
Wang, D. S., Iwata, N., Hama, E., Saido, T. C., and Dickson, D. W. (2003). Oxi-
dized neprilysin in aging and Alzheimer’s disease brains. Biochem. Biophys. Res.
Commun. 310, 236–241. doi: 10.1016/j.bbrc.2003.09.003
Wang, S. S., Rymer, D. L., and Good, T. A. (2001). Reduction in cholesterol and sialic
acid content protects cells from the toxic effects of beta-amyloid peptides. J. Biol.
Chem. 276, 42027–42034. doi: 10.1074/jbc.M102834200
Weidemann,A., Konig, G., Bunke, D., Fischer, P., Salbaum, J. M.,Masters, C. L., et al.
(1989). Identiﬁcation, biogenesis, and localization of precursors of Alzheimer’s
disease A4 amyloid protein. Cell 57, 115–126. doi: 10.1016/0092-8674(89)
90177-3
Frontiers in Aging Neuroscience www.frontiersin.org May 2014 | Volume 6 | Article 91 | 16
Wong et al. Metals and cholesterol in AD
White, A. R.,Multhaup, G.,Maher, F., Bellingham, S., Camakaris, J., Zheng, H., et al.
(1999a). The Alzheimer’s disease amyloid precursor protein modulates copper-
induced toxicity and oxidative stress in primary neuronal cultures. J. Neurosci.
19, 9170–9179.
White, A. R., Reyes, R., Mercer, J. F., Camakaris, J., Zheng, H., Bush, A.
I., et al. (1999b). Copper levels are increased in the cerebral cortex and
liver of APP and APLP2 knockout mice. Brain Res. 842, 439–444. doi:
10.1016/S0006-8993(99)01861-2
Whitehouse, P. J. (1997). Genesis of Alzheimer’s disease. Neurology 48, S2–S7. doi:
10.1212/WNL.48.5_Suppl_7.2S
Wood, W. G., Schroeder, F., Avdulov, N. A., Chochina, S. V., and Igbavboa, U.
(1999). Recent advances in brain cholesterol dynamics: transport, domains,
and Alzheimer’s disease. Lipids 34, 225–234. doi: 10.1007/s11745-999-
0357-9
Wu,W.H., Lei, P., Liu,Q.,Hu, J., Gunn,A. P., Chen,M. S., et al. (2008). Sequestration
of copper from beta-amyloid promotes selective lysis by cyclen-hybrid cleavage
agents. J. Biol. Chem. 283, 31657–31664. doi: 10.1074/jbc.M804722200
Xu, X., and London, E. (2000). The effect of sterol structure on membrane lipid
domains reveals how cholesterol can induce lipid domain formation. Biochemistry
39, 843–849. doi: 10.1021/bi992543v
Yamauchi, K., Tozuka, M., Hidaka, H., Nakabayashi, T., Sugano, M., and Kat-
suyama, T. (2002). Isoform-speciﬁc effect of apolipoprotein E on endocytosis
of beta-amyloid in cultures of neuroblastoma cells. Ann. Clin. Lab. Sci. 32,
65–74.
Yamauchi, K., Tozuka, M., Hidaka, H., Nakabayashi, T., Sugano, M., Kondo, Y.,
et al. (2000). Effect of apolipoprotein AII on the interaction of apolipopro-
tein E with beta-amyloid: some apo(E-AII) complexes inhibit the inter-
nalization of beta-amyloid in cultures of neuroblastoma cells. J. Neurosci.
Res. 62, 608–614. doi: 10.1002/1097-4547(20001115)62:4<608::AID-JNR16>3.0.
CO;2-4
Yan, R., Bienkowski, M. J., Shuck, M. E., Miao, H., Tory, M. C., Pauley, A. M.,
et al. (1999). Membrane-anchored aspartyl protease with Alzheimer’s disease
beta-secretase activity. Nature 402, 533–537. doi: 10.1038/990107
Yang, D. S., Small, D. H., Seydel, U., Smith, J. D., Hallmayer, J., Gandy, S. E.,
et al. (1999). Apolipoprotein E promotes the binding and uptake of beta-amyloid
into Chinese hamster ovary cells in an isoform-speciﬁc manner. Neuroscience 90,
1217–1226. doi: 10.1016/S0306-4522(98)00561-2
Yip, C. M., Elton, E. A., Darabie, A. A., Morrison, M. R., and Mclaurin, J.
(2001). Cholesterol, a modulator of membrane-associated Abeta-ﬁbrillogenesis
and neurotoxicity. J. Mol. Biol. 311, 723-734. doi: 10.1006/jmbi.2001.4881
You, H., Tsutsui, S., Hameed, S., Kannanayakal, T. J., Chen, L., Xia, P., et al. (2012).
Abeta neurotoxicity depends on interactions between copper ions, prion protein,
and N-methyl-D-aspartate receptors. Proc. Natl. Acad. Sci. U.S.A. 109, 1737–
1742. doi: 10.1073/pnas.1110789109
Zampagni,M., Evangelisti, E., Cascella, R., Liguri, G., Becatti,M., Pensalﬁni,A., et al.
(2010). Lipid rafts are primary mediators of amyloid oxidative attack on plasma
membrane. J. Mol. Med. (Berl.) 88, 597–608. doi: 10.1007/s00109-010-0603-8
Zelcer, N., Khanlou, N., Clare, R., Jiang, Q., Reed-Geaghan, E. G., Landreth, G. E.,
et al. (2007). Attenuation of neuroinﬂammation and Alzheimer’s disease pathol-
ogy by liver x receptors. Proc. Natl. Acad. Sci. U.S.A. 104, 10601–10606. doi:
10.1073/pnas.0701096104
Zheng, H., and Koo, E. H. (2011). Biology and pathophysiology of the amyloid
precursor protein. Mol. Neurodegener. 6, 27. doi: 10.1186/1750-1326-6-27
Zhou, Y., and Richardson, J. S. (1996). Cholesterol protects PC12 cells from beta-
amyloid induced calciumdisordering and cytotoxicity.Neuroreport 7, 2487–2490.
doi: 10.1097/00001756-199611040-00017
Zlokovic, B. V. (2008). The blood–brain barrier in health and chronic neurodegen-
erative disorders. Neuron 57, 178–201. doi: 10.1016/j.neuron.2008.01.003
Conflict of Interest Statement:The authors declare that the researchwas conducted
in the absence of any commercial or ﬁnancial relationships that could be construed
as a potential conﬂict of interest.
Received: 28 February 2014; accepted: 28 April 2014; published online: 15 May 2014.
Citation:Wong BX,Hung YH, Bush AI and Duce JA (2014) Metals and cholesterol: two
sides of the same coin in Alzheimer’s disease pathology. Front. Aging Neurosci. 6:91.
doi: 10.3389/fnagi.2014.00091
This article was submitted to the journal Frontiers in Aging Neuroscience.
Copyright © 2014 Wong, Hung, Bush and Duce. This is an open-access article dis-
tributed under the terms of the Creative Commons Attribution License (CC BY). The
use, distribution or reproduction in other forums is permitted, provided the original
author(s) or licensor are credited and that the original publication in this journal is cited,
in accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
Frontiers in Aging Neuroscience www.frontiersin.org May 2014 | Volume 6 | Article 91 | 17
